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ABSTRACT
Several human and animal studies of chromium (Cr) supplementation in 
the form of Cr picolinate (CrPic) have reported increases in lean body mass, 
often with concurrent body fat decreases. This 12-week study examined the 
effects of six dietary levels of CrPic (0, 75,150, 300, 600, 1500 ppb Cr) upon the 
growth and body composition of the rat.
Ninety male Harlan Sprague-Dawley outbred weanling rats arrived in three 
groups of 30 animals (referred to as Blocks 1, 2, and 3). Five animals from each 
block were assigned to each treatment, resulting in a 6 X 3 (treatment X block) 
Randomized Block Design.
Body composition was assessed via dual emission X-ray absorptiometry 
(DEXA). Significant treatment X block interactions were found for fat weight (p 
= 0.01 and 0.06 at Weeks 5 and 10), percent body fat (p = 0.02 and 0.09 at 
Weeks 5 and 10), and body weight (p = 0.07 and 0.04 at Weeks 10 and 12). 
These interactions reflected decreases in body fat for Block 1 that corresponded 
with increasing CrPic levels.
No treatment interactions or effects were seen for growth rate, lean body 
mass, or tissue weights, but most block effects were highly significant (p = 
0.01), with Block 2 > Block 3 > Block 1. These significant block effects were 
further reflected in the glucose tolerance data, in which Block 1 had lower resting 
glucose levels than Block 2 (p = 0.07) and lower glycated hemoglobin levels 
than both Blocks 2 and 3 (p = 0.09).
x
A significant treatment X block interaction (p = 0.01) for feed intake 
revealed a decrease for Blocks 1 and 2, but an increase for Block 3, at the 
highest CrPic level. However, only Block 1 experienced corresponding changes 
in body composition. Furthermore, except for the highest CrPic level, body fat 
reductions for Block 1 occurred without decreases in feed intake, implicating 
possible dietary-induced thermogenic effects of CrPic.
Genetic differences could have accounted for some of the differential 
effects of CrPic supplementation upon the blocks of animals. Additionally, more 
stringent Cr-free conditions may be necessary for changes in growth rate to 
occur, and exercise may be an important stimulus for potentiating increases in 
lean body mass.
xi
CHAPTER 1. INTRODUCTION
The realization that chromium (Cr) may be an essential dietary ingredient 
began with the observation that rats fed a diet made with Torula yeast developed 
an impaired glucose tolerance (124). Schwarz and Mertz (167) hypothesized 
that a dietary component, deficient in Torula yeast, was necessary for normal 
glucose tolerance. This agent was termed "glucose tolerance factor" (GTF), and 
its best known function is the potentiation of insulin (116). Although the exact 
structure of GTF is yet unknown (2), Cr has been identified as its active 
ingredient (168). The mechanism in which Cr potentiates insulin action has not 
been elucidated, although likely theories include an enhancement of insulin- 
insulin receptor binding (113, 118) and increased production or membrane 
insertion rate of the insulin receptor (3, 51).
Inorganic Cr compounds are thought to have no biological activity until 
they are converted to the active GTF complex. The best known possible source 
of dietary GTF is Brewer’s yeast. It is believed that Brewer’s yeast is able to 
transform inorganic forms of Cr into a complex that is better absorbed and that 
appears to have greater biological activity (28, 116). Compared to Cr from 
inorganic sources, Cr extracted from Brewer’s yeast was found to have a 
different tissue distribution, to have access to the pool that is the source of the 
acute plasma rise in response to insulin, and to be transported across the 
placenta (116). These findings have led to the classification of Cr into either 
"simple" compounds with little or no biological activity, or compounds with
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outstanding insulin potentiating activity in vitro and in vivo. It is this latter 
category that has been termed GTF (116). In addition to obtaining GTF in the 
diet, it is thought that inorganic Cr compounds are converted to a biologically 
active form in mammals, although it is not certain where this transformation 
occurs (2, 182).
Although Cr can occur in every oxidation state from -2 to +6, it is the 
trivalent, or +3 state that is most likely to function in biological systems (113). 
Furthermore, it is the trivalent state that has been found in Brewer’s yeast and 
other dietary sources of Cr (168). By weight, the foods containing the most Cr 
are oysters, raisins, mushrooms, Brewer’s yeast, cocoa, black pepper, molasses, 
and grape juice (7, 103). Since the amount of Cr with GTF activity may be more 
important than total Cr (116), foods have also been categorized by content of 
biologically active Cr. In terms of Cr with GTF activity, foods with the highest 
content include Brewer’s yeast, black pepper, liver, animal meats, and whole 
grains (103, 126).
It has been suggested that GTF is a complex of Cr, nicotinic acid, and 
amino acids (116, 179). However, it has also been suggested that GTF may be 
a complex of Cr and picolinic acid (48). Furthermore, synthetic complexes of Cr 
with nicotinic acid (CrNic) and of Cr with picolinic acid (CrPic) have been shown 
to have some degree of biological activity (27, 48, 50, 51, 54, 73, 78, 79, 80, 88, 
93, 102, 115, 117, 137, 142). When administered to rats orally, intravenously, or 
through stomach tubing, CrNic complexes were found to decrease fasting
glucose levels and to enhance glucose clearance rates in response to a glucose 
tolerance test (GTT) (115, 117). Studies of oral CrPic supplementation have 
observed decreased fasting glucose levels in humans and rats (48, 50, 54), 
enhanced glucose clearance rates in response to a GTT in calves (27), and 
decreased glycated hemoglobin levels in humans and rats (54). Furthermore, 
studies have supported increases in body weight (48,80), increases in lean body 
mass (48, 54, 78, 88, 93, 102, 137), and decreases in body fat levels (48, 88, 93, 
102, 137) in both humans and animals whose diets were supplemented with 
CrPic. Additionally, cell culture studies of skeletal myoblasts have indicated that 
CrPic enhances the uptake of glucose and L-leucine into the cell (51, 79).
The toxicity of Cr is low, but deficiencies in the U.S. may be common due 
to low intakes of Cr and high consumption of refined foods and simple sugars 
(8, 113). Although a daily requirement has not been set, the 1989 National 
Research Council recommends 50 to 200 jug/day as a safe and adequate intake 
for humans (132). However, it was found that approximately 90% of the freely- 
chosen U.S. diets that were analyzed contained less than the minimum 
recommendation of 50 jug/day. Furthermore, the absorption of Cr is low, about 
0.4% for inorganic Cr (45), and from 0.5 to 2.0% for dietary sources of Cr (8). 
Synthetic CrNic and CrPic complexes appear to be absorbed three- to fourfold 
that of inorganic Cr 49, 116), but still less than the 10 to 25% absorption for Cr 
from Brewer’s yeast (116).
Once absorbed, Cr binds to transferrin in the blood (84). The uptake and 
retention of Cr appears to be greatest for liver, kidney, spleen, testes, epididymis, 
and bone (82, 95, 186). Except for the lung, human tissue levels of Cr decrease 
with age (178). Most absorbed Cr is excreted in the urine (113), and therefore 
Cr excretion is a meaningful indicator of Cr intake (11). Urinary Cr losses can 
be increased by factors such as high glucose (14) and sucrose (94, 156) 
consumption, physical trauma (23), and exercise (5, 7, 9, 13, 30).
It has been demonstrated that animals raised under Cr-deficient conditions 
develop a progressive impairment of glucose tolerance (122, 124, 153, 154). 
This impairment can be prevented or reversed by supplementation with a variety 
of Cr complexes, including Brewer’s yeast (125), CrNic (115, 117), CrPic (27), or 
inorganic Cr compounds (122). In addition to enhancing glucose clearance 
rates in response to a glucose challenge, Cr supplementation has been shown 
to lower resting blood glucose (48, 50, 54, 104, 115, 117, 128, 145, 153, 154) 
and glycated hemoglobin (48, 54) levels. Although marginal Cr deficiency may 
impair glucose tolerance, more stringent Cr-free conditions may depress growth 
rates, at least in the rodent (119, 122).
Although most of the research in the past has examined the interaction 
of Cr and insulin in regard to glucose metabolism, insulin also has a key role in 
muscle metabolism (57, 71). In addition to enhancing glucose and amino acid 
uptake into muscle cells (81), insulin inhibits enzymes that catabolize amino 
acids and protein (57). Together these factors may cause increased anabolic
5and decreased catabolic processes in the muscle cell. Due to the effects of 
insulin to enhance muscle glycogen synthase activity (22), glucose storage as 
well as uptake may be enhanced. Therefore, Cr supplementation could 
potentiate the actions of insulin to increase muscle protein and/or glycogen 
content. Furthermore, these effects may be greater in muscles with greater white 
than red fiber compositions, since insulin sensitivity appears to be greater in 
muscles of predominantly white or mixed fiber versus red fiber types (63, 86).
Additionally, it has been shown that Cr supplementation may reduce body 
fat levels (48, 88, 93, 102, 137). Although the anabolic effects of Cr may be 
expected due to its interaction with insulin, the decrease in body fat is harder to 
explain, since insulin also increases lipogenesis in the liver and in adipose tissue 
(76, 189). However, Cr may stimulate dietary-induced thermogenesis by 
promoting insulin-mediated activation of the sympathetic nervous system (58, 
111,150,151). Additionally, muscle tissue is more insulin-resistant than adipose 
tissue when levels of circulating insulin are high (18). Therefore, if Cr 
supplementation were to enhance insulin sensitivity in muscle tissue, the 
stimulus for fat production would be reduced. Furthermore, Cr potentiation of 
insulin could play a permissive role in growth hormone action (72), leading to 
reductions in body fat as well as increases in lean body mass (76).
The combination of low Cr intakes (8, 97) and increased urinary losses of 
Cr due to exercise (5, 7, 9, 13, 30) may predispose athletes to a marginal Cr 
status (80, 100). Therefore, it has been suggested that if athletes are given Cr
6in a bioavailable form, they may experience an increase in muscle mass and/or 
strength with a possible concurrent reduction in body fat in excess of that due 
to training alone (48, 80). In response to these suggestions, synthetic Cr 
supplements (e.g., CrNic and CrPic) have recently appeared in the health and 
fitness market (188). Companies promoting these products have targeted the 
athletic community, claiming proven effects of increased muscle mass and 
decreased body fat. Both human (48, 54, 80, 88) and animal (78, 93,102,137) 
studies of CrPic supplementation have supported these claims to varying 
degrees.
In human studies, CrPic in doses of 200 to 400 £jg/day appeared to 
increase lean body mass (48, 54, 88), but CrNic in doses of 200 to 800 jug/day 
did not (54, 98). Chromium picolinate supplementation also appeared to 
decrease body fat levels in some cases (48, 88), but again CrNic did not (98). 
Furthermore, two studies of CrPic supplementation have reported increases in 
body weight (48, 80), although this was not seen for CrNic supplementation (98).
Several animal studies have observed increases in lean body mass (78, 
93, 102, 137) and decreases in body fat (93, 102, 137) due to Cr 
supplementation in the form of CrPic. The dosages of CrPic in these studies 
ranged from 25 to 1000 ppb Cr added to the feed. In the swine, Page et al. 
(137) found that these body composition changes took place at Cr levels of 100, 
200, 400, and 800 ppb Cr, but that growth rate was decreased at the higher 
levels of 400 and 800 ppb due to a depression of feed intake. However,
7Lindemann et al. (102) found linear increases in lean body mass with linear 
decreases in body fat in the swine for CrPic additions of 100, 200, and 1000 ppb 
Cr. No changes in daily feed intake nor feed efficiency (i.e., rate of growth per 
unit of feed consumption) were reported.
Furthermore, body composition changes in the swine occurred without 
any alterations in resting blood glucose levels (137). Therefore, at least in one 
case (137), changes in body composition due to Cr supplementation took place 
even though marginal Cr deficiency was not evident in the control groups. 
However, none of the other studies (78, 93,102) that reported body composition 
changes conducted any measures of glucose tolerance.
The purpose of the current study was to examine the effect of different 
levels of CrPic in the diet of the rat on growth and body composition changes 
under normal laboratory conditions. Possible effects of CrPic supplementation 
upon feeding behavior were also examined. It was hypothesized that increases 
in lean body mass with possible decreases in body fat would occur with 
increasing CrPic dosage. Body weight was expected to increase with lean body 
mass, but only to the degree that gains may be counteracted by body fat 
reductions. These changes in body composition were expected to occur mainly 
without concurrent changes in growth rate, feed intake, or feed efficiency. 
Furthermore, the glucose tolerance of the animals was examined to determine 
if changes in growth and/or body composition were accompanied by alterations 
in glucose metabolism.
Since insulin sensitivity varies according to muscle fiber type (60, 63, 86, 
87, 139), possible differential effects of Cr upon muscles of different fiber 
composition were also examined. Furthermore, previous studies have not 
documented whether increases in lean body mass due to Cr supplementation 
were due to increases in muscle glycogen and/or protein content. Further 
analyses were therefore planned for organs and muscles of animals in any of the 
treatment groups that may have had significant increases in tissue weights 
and/or overall lean body mass.
CHAPTER 2. REVIEW OF LITERATURE
2.1. CHROMIUM COMPOUNDS AND DIETARY REQUIREMENTS
Chromium can occur in every oxidation state from -2 to +6, but the 
trivalent, or +3 state is the most stable and the most likely to function in 
biological systems (113). It is the trivalent state that has been found to occur in 
fractions from Brewer’s yeast with GTF activity (168). Trivalent Cr has a 
coordination number of 6, and in aqueous solution it is always coordinated with 
water or other ligands. Chromium complexes are quite stable at acidic pH, but 
at nearly neutral physiological pH, hydrolysis of coordinated water molecules 
takes place, resulting in hydroxyl groups that may coordinate with each other. 
The hydroxyl groups may form bridges between complexes, in a process called 
olation (113). The olation process leads to large insoluble complexes with little 
or no biological activity (149). However, Cr compounds can be protected from 
olation by coordination to ligands that can compete against the olating tendency 
of an excess of hydroxyl ions (148).
The chemical environment as well as the valence state determines the 
biological effect of Cr. Whereas inorganic Cr salts have a delayed effect in vitro. 
Brewer’s yeast extracts act immediately (28). Similar findings have been found 
in vivo. Several weeks of supplementation with chromic chloride (CrCI3) was 
necessary for the improvement of glucose tolerance of human subjects, and this 
lag phase could not be shortened by increasing the dose (69). However, normal 
glucose tolerance in the rat was restored only 1-2 weeks after adding Brewer’s
9
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yeast concentrates to the diet (125). Furthermore, simple Cr salts do not cross 
the placenta and intestinal absorption does not appear to depend on the 
nutritional Cr status of the animal (121). Additionally, simple Cr salts were found 
not to equilibrate with the pool that is responsible for the acute plasma Cr rise 
in response to insulin (120).
Experiments with Brewer’s yeast extracts have suggested that yeast is 
able to transform inorganic Cr into a complex that more nearly meets the criteria 
of an essential element (28). Compared to Cr from CrCI3, Cr extracted from 
Brewer’s yeast was found to be better absorbed, to have a different tissue 
distribution, to have access to the pool that is the source of the acute plasma 
rise in response to insulin, and to be transported across the placenta (116).
These findings have led to the hypothesis of two classes of Cr 
compounds: "simple" compounds with little or no biological activity, and
compounds with outstanding insulin potentiating activity in vitro and in vivo. This 
latter category is termed GTF, and may consist of one or several closely related 
compounds (116). Mertz and Schwarz (125) have suggested that GTF meets the 
criteria of an essential dietary ingredient since it is a naturally occurring 
compound whose lack in the diet produces an impairment, the impairment can 
be prevented by supplementation, and it is effective in physiological doses.
Although the exact structure of GTF is not known (2), it has been 
concentrated from Brewer’s yeast and pork kidney powder (125). It is water- 
soluble, but extractable with phenol and isobutanol (125). Fractions of GTF were
found to contain nicotinic acid through mass spectrometry, as well as the amino 
acids glycine, glutamic acid, and cysteine (179). However, not all Cr in 
biological material has GTF activity, since biological function is not significantly 
correlated to the total Cr content of different materials (179).
Inorganic Cr compounds are thought to have no biological activity until 
they are converted to the active GTF complex. It is not certain where this 
transformation occurs in mammals (2,182), although Mertz (116) has suggested 
that it may be the intestinal flora or the liver. Although it has been assumed that 
the GTF synthesized in mammals is a complex of Cr, nicotinate, and amino acids 
(116, 179), Evans (48) has suggested that GTF may actually be a complex of Cr 
and picolinate. Furthermore, both kidney and yeast have been identified as 
excellent sources of biologically active Cr and cells from both of these sources 
produce high levels of picolinic acid (85, 129).
Picolinate (pyridine-2-carboxylate) is an end-product of tryptophan 
metabolism (47). Synthetic complexes of Cr and picolinic acid have been 
prepared (51, 54), and the CrPic complex that has been shown to be active in 
the skeletal muscle cell assay (51, 54, 79) and in vivo (48, 54, 73, 78, 80, 88, 
137, 142) is a tripicolinate complex (54). Due to the position of the carboxyl 
group, picolinate forms a bidentate coordination with trivalent Cr through the 
carboxyl oxygen and pyridine nitrogen (176). This complex forms readily at 
37°C, is uncharged at all hydrogen ion concentrations, and is slightly soluble in
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water (54). However, its high solubility in chloroform suggests that this complex 
has good membrane permeability (54, 110).
By weight, the foods containing the most Cr are oysters, raisins, 
mushrooms, Brewer’s yeast, cocoa, black pepper, molasses, and grape juice (7, 
103). Two studies (67, 180) found that meats and whole grains were good 
sources of Cr, but fruits, vegetables, and milk were found to have low Cr levels 
(67). Since the amount of Cr with GTF activity may be more important than total 
Cr (116), foods have also been categorized by content of biologically active Cr. 
Using the 50% ethanol extraction method (180), black pepper, liver, animal 
meats, and whole grains follow Brewer’s yeast in biological activity (103, 126).
Mertz (114) has estimated the daily requirement of Cr to be 10 to 30 jug 
from good sources of GTF such as Brewer’s yeast. Although a daily requirement 
has not been set, the 1989 National Research Council, National Academy of 
Sciences, recommends 50 to 200 /j q  Cr/day as a safe and adequate intake 
(132). Furthermore, trivalent Cr is among the safest trace elements, with a 
therapeutic:toxic ratio of approximately 1:10,000 for intravenous injection (113). 
No known reports of oral toxicity of Cr have been made to date.
Although toxicity is low, Cr deficiencies in the U.S. may be common (8, 
113). Many Americans consume diets low in Cr (8, 97) and high in refined foods 
and simple sugars (94, 157). Simple sugars such as glucose (14) and sucrose 
(94, 156) have been shown to increase urinary Cr losses. Anderson and 
Kozlovsky (8) found that approximately 90% of the freely-chosen diets analyzed
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contained less than the minimum suggested safe and adequate daily intake of 
50 jug Cr. The mean Cr intake was found to be only 15 jug per 1000 kcal. Two 
other studies reported a wide variation in daily Cr intake, from 5 to 115 jug (101, 
158). The source of animal protein played a factor, since the diets containing 
meat had higher Cr levels than those containing fish and seafood (158). 
Therefore, suboptimal Cr intakes may be due largely to dietary preferences.
2.2. CHROMIUM METABOLISM 
Inorganic Cr is poorly absorbed from the gastrointestinal tract (8, 11, 43, 
121, 186). In the rat, Visek et al. (186) reported that less than 0.5% of an oral 
dose of Cr as CrCI3 was absorbed. In the vascular perfusion technique, Dowling 
et al. (45) found that the rat small intestine took up approximately 0.4% of the 
dose, regardless of CrCI3 concentration. Since most of the absorbed Cr is 
excreted in the urine (113), urinary Cr is often used as an indicator of Cr 
absorption in human subjects (8, 11, 43). Donaldson and Barreras (43) found 
that only 0.1 to 1.2% of an oral dose of Cr from CrCI3 appeared in the urine of 
human subjects. Similarly, Anderson et al. (11) estimated minimum Cr 
absorption from CrCI3 to be 0.4% in healthy adults.
Whereas most studies report that inorganic trivalent Cr is absorbed by 
passive diffusion (43, 45, 121), it has also been suggested that carrier proteins 
may be involved (120). The former conclusion was based on evidence that 
absorption of Cr did not appear to be a saturable process (121) and that the 
percentage of Cr taken up by the small intestine was the same regardless of the
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concentration (45). However, Mertz and Roginski (120), using everted gut sacs, 
found that the percentage of absorbed Cr decreased as the concentration in the 
incubation media increased. Furthermore, fasted rats have been shown to 
absorb Cr at a significantly greater rate than nonfasted ones (35).
Dowling et al. (45), using the vascularly perfused rat small intestine, 
concluded that inorganic trivalent Cr is absorbed by the small intestine through 
passive diffusion and is independent of nutritional status. However, they did not 
preclude the possibility that other forms of Cr or that inorganic Cr under certain 
conditions may be absorbed by carrier-mediated transport. They suggested that 
Cr could pass through aqueous channels in the plasma membrane or through 
tight junctions acting as paracellular shunts. Using the everted gut sac 
technique, the midsection of the rat intestine appeared to be the most diffusible 
segment for Cr, followed by the ileum and duodenum (35).
The degree of absorption may depend upon the ability of ligands to 
protect against olation (148). When a combination of oxalate and CrCI3 was 
given to rats, absorption of Cr was increased (35). The presence of oxalate 
probably protected Cr from undergoing olation by serving as a ligand to Cr, 
thereby replacing the hydroxyl groups. It has also been suggested that ligands 
present in the intestine may coordinate with Cr, making it soluble and available 
for absorption (149). However, it can be assumed that natural complexes in the 
diet that are already coordinated with ligands are better absorbed than simple 
salts (121).
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For human subjects on freely-chosen diets, estimated Cr absorption 
ranged from 0.5 to 2.0%, and it appeared to be inversely related to intake (8). 
However, another study (11) found that absorption of Cr as determined from 
urinary excretion was similar, approximately 0.4%, from both CrCI3 and from 
foods. Perhaps the means and the degree of Cr absorption depends upon the 
form of Cr that is predominant in the diet.
Brewer’s yeast Cr is absorbed 10 to 25% by the rat, which is significantly 
better than Cr from CrCI3 (116). Synthetic CrNic complexes are also absorbed 
significantly better than CrCI3 (116, 126), probably by a factor of three to four 
(116). Picolinate has been shown to improve zinc absorption in both animals 
and humans (46, 96). Like zinc, Cr is also a transition element, and CrPic is 
probably also absorbed to a greater extent than simple Cr salts. The 
requirement of Cr as CrPic has been estimated to be only one-third that of 
unchelated Cr (49).
Once absorbed, trivalent Cr has been shown to be bound to transferrin 
in the blood. In normal physiological amounts the binding appears to be 
specific, with an affinity for the metal binding site of iron (84). The binding of Cr 
to transferrin is firm enough to prevent olation and other reactions in the blood 
but loose enough to release Cr at the tissues (112).
Animal studies have shown that the uptake and retention of Cr is greatest 
in the liver, kidney, spleen, testes, epididymis, and bone (82, 95, 186). Uptake 
of Cr is particularly great for the bone marrow (95, 186). The retention of Cr was
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found to be greater in the bones for young growing rats, but the adult rats had 
greater retention in the spleen, kidney, testes, and epididymis (82). Brain and 
muscle do not take up much Cr (95, 186). However, after 5 weeks of CrCI3 
supplementation in turkey hens, a small but statistically significant increase of Cr 
did occur in the breast but not the leg tissue (6).
Tissue levels of Cr were found to decrease with age in mice (187). The 
levels of retained Cr in liver, stomach, epididymis, thymus, kidney, and testes 
was nearly two-fold for the younger animals. This corresponds to decreasing Cr 
levels found with age for the U.S. population (158). This decline could be due 
to a normal process, in which Cr that is no longer needed is eliminated, or it 
could be due to chronic suboptimal dietary intakes (113). The naturally 
decreasing tissue Cr levels in aging rats (158) tends to support the first 
contention.
Tissue Cr concentrations are high in the newborn, but they begin to 
decline during the first few months of life for the aorta, heart, and spleen. After 
ten years they begin to decline in the kidney and lung. All tissues show a further 
decline for the rest of life except for the lung which steadily increases after 20 
years (178). Since trivalent Cr is quite insoluble it remains in the lung to a large 
extent and is unable to exchange with other body stores (19). Therefore, only 
hexavalent chromate, soluble in water droplets, is available to the rest of the 
body upon inhalation (113). This may account for the higher tissue Cr levels of 
persons living in industrialized areas (158).
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Studies using graphite furnace atomic absorption spectrometry (GF-AAS) 
have found basal urinary Cr excretion values of healthy adults to be 
approximately 0.20 to 0.24 jug/day (11, 94). Since 95 percent of absorbed Cr is 
excreted in the urine (113), it has been suggested that the Cr nutritional status 
of individuals may be estimated through daily urinary losses (41, 42, 82). 
Anderson et al. (11) found that basal urinary Cr losses in humans increased 
approximately fivefold from 0.20 to 0.99/jg/day during a supplementation period 
of 200 f jg Cr/day as CrCI3. These authors concluded that Cr excretion was a 
meaningful indicator of Cr intake but not necessarily status. Furthermore, urinary 
Cr does not give a complete measure of Cr excretion since the intestines also 
appear to play a part (82) and the amount of Cr lost through sweat has not been 
established (30).
Factors such as high glucose (14) and high sucrose (94, 156) 
consumption, physical trauma (23), and exercise (5, 7, 9, 13, 30) can increase 
urinary Cr losses. In the rat, Schroeder (156) found that high sucrose 
consumption nearly doubled urinary Cr losses, and Kozlovsky et al. (94) found 
that most human subjects had variable increases in urinary Cr excretion ranging 
from 10% to 300% when given a high sucrose diet compared to a basal low 
sucrose diet. For trauma patients, urinary Cr losses were elevated more than 50- 
fold within 24 hours of injury, and were still elevated 10-fold one week later. 
These losses were accompanied by increases in serum glucose levels (23).
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Stressors such as physical exercise may increase the urinary excretion of 
Cr several-fold (5, 7, 9, 13, 30). Additionally, the urinary excretion for trained 
runners has been found to be greater than that of sedentary subjects after a 
bout of strenuous exercise (5). However, the basal urinary Cr excretion of the 
trained runners was less than that of the control subjects on a nonexercise day 
(5). Perhaps this reflects a training adaptation whereby athletes are able to 
conserve Cr (30). Conversely, the tissue levels of the athletes may have been 
depleted and the plasma levels were decreased in order to replenish the tissue 
levels. In the rat, Vallerand et al. (184) found that training leads to increased 
levels of Cr in the heart and kidney, but not the liver nor gastrocnemius muscle. 
Regardless, the overall trend in these studies appears to be an increase in acute 
urinary Cr losses after exercise.
Factors such as high consumption of simple sugars, trauma, and exercise 
most likely increase glucose metabolism, thereby increasing Cr mobilization (94). 
Glinsmann and colleagues (68, 69) found that plasma Cr levels in young, healthy 
subjects increased approximately two-fold 30 to 120 minutes after a 100 gram 
oral glucose challenge. Insulin injections also cause acute plasma Cr 
increments, suggesting that the response of plasma Cr to glucose is indirect, 
occurring through the secretion of insulin (126). Since renal reabsorption of Cr 
is less than 5% (42), an increase in urinary losses will ultimately occur. 
Therefore, it is likely that any condition that results in an increase in plasma 
insulin levels will increase dietary Cr requirements (126).
2.3. CHROMIUM AND INSULIN ACTION
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Insulin is a polypeptide hormone that is synthesized as a single-stranded 
proenzyme within the p cells of the pancreas. Upon cleavage of a connecting 
peptide of 31 amino acid residues, the insulin molecule is a dimer consisting of 
an A and B chain of 21 and 30 amino acids, respectively (76). As a result of 
three dimensional folding, both the A and B chains come together to comprise 
the binding domain of the insulin molecule (89).
Insulin is released from the pancreas during meal absorption in response 
to increased plasma levels of glucose and/or amino acids (76). Insulin has 
profound effects on protein metabolism in many cell types (32, 63, 64, 86, 87, 
172). Mechanisms of insulin action upon protein synthesis appear to include 
activation of amino acid and hexose transport systems (39), an increase in the 
number of ribosomes (77, 86), an increase in peptide chain initiation (74, 77, 86, 
87), and changes in mRNA levels (86). Additionally, net protein anabolism in the 
presence of insulin may take place due to a suppression of endogenous 
catabolic processes (65, 177), and elevations of plasma insulin concentrations 
have been shown to inhibit proteolysis in a dose-dependent manner (172).
Furthermore, insulin acts synergistically with a number of other anabolic 
hormones such as growth hormone (76) and the insulin-like growth factors (76, 
81). Although insulin appears to promote cellular growth of some tissues 
through a direct action, its effect upon musculoskeletal growth may be largely 
due to indirect actions through other growth factors, particularly the insulin-like
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growth factors (81). It is possible that Cr potentiates these other growth factors 
as well as insulin (110).
The insulin receptor consists of two cr- and two p-subunits. The a- 
subunits contain the insulin binding sites, whereas the p-subunits transcend the 
cell membrane and are involved in the intracellular signaling (89, 90). Upon 
binding of insulin to the a-subunit, an inhibitory effect upon the p-subunit is 
eliminated. The p-subunit most likely transmits its signal via a phosphorylation 
cascade or a noncovalent interaction pathway (90).
The insulin receptor is present on virtually all cell types, but the 
concentration may vary from as few as 40 receptors on erythrocytes to more 
than 200,000 receptors on adipocytes and hepatocytes (90). The functions of 
the insulin receptor include binding the insulin molecule with a high degree of 
affinity and specificity, and then transmitting a transmembrane signal (89, 90).
Insulin is capable of regulating the absolute amount of some intracellular 
proteins by means of gene expression (77, 86). Additionally, using isolated 
perfused preparations of rat heart and gastrocnemius muscle, Jefferson and 
colleagues (86, 87) have demonstrated that a lack of insulin results in a decrease 
in protein synthesis after the first hour. Sucrose gradient analysis of polysomes 
and ribosomal subunits revealed that there was an accumulation of ribosomal 
subunits and a fall in polysomes in both the heart (86) and gastrocnemius (87) 
muscles. Therefore, the decrease in protein synthesis seen after 1 hour was due 
to a restraint on peptide-chain initiation. Addition of insulin to the perfusate
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maintained normal levels of protein synthesis and in vivo levels of polysomes 
and ribosomal subunits (86, 87).
In a subsequent study (60), the gastrocnemius, soleus, and heart muscles 
from rats made diabetic by injection of alloxan monohydrate were examined after 
two days. Compared to tissues from control animals, the rate of protein 
synthesis was greatly reduced in the gastrocnemius, slightly reduced in the 
soleus, but not altered in the heart. The decrease in protein synthesis in the 
gastrocnemius was due to both a loss of tissue RNA and a reduction in 
translational efficiency (i.e., synthesis per unit RNA). However, the soleus 
demonstrated a reduction in RNA content, but no decrease in translational 
efficiency (60).
Another study (139) examined the in vivo rates of protein synthesis in 
muscle tissues of rats made diabetic by injection of streptozotocin five days 
earlier. Diabetes resulted in 70% and 44% reductions of protein synthesis in 
skeletal muscle and the heart, respectively. Levels of ribosomal subunits were 
elevated in the gastrocnemius and psoas muscles, slightly increased in the 
soleus muscle, but unchanged in the heart (139). Therefore, polysomal 
disaggregation, indicative of an impaired peptide-chain initiation process, 
appeared to be greater in muscles with mixed fiber distributions (i.e., 
gastrocnemius and psoas) than in a muscle comprised predominantly of red 
fibers (i.e., soleus), both in vitro and in vivo (139). Furthermore, data from two
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of these studies (86, 139) demonstrate that insulin deficiency does not block 
translational efficiency in the heart.
Many sources claim that the primary effect of insulin on protein 
metabolism is an inhibition of proteolysis (32, 59,64). However, insulin has been 
shown to have a stimulatory effect upon protein synthesis, particularly in vitro 
(63, 66, 107). Two in vivo studies (32, 64) emphasized the importance of both 
high insulin and high amino acid levels for enhancement of protein synthesis. 
It has been hypothesized that insulin does exert a stimulatory effect on protein 
synthesis, but that this effect is only seen at pharmacologic levels often used in 
vitro (32). However, one in vitro study (63) found that protein synthesis in both 
the soleus and extensor digitorum longus of the mouse was significantly 
stimulated when insulin was added in physiological concentrations. In this case, 
however, the effect of insulin to decrease protein catabolism was seen only in 
the extensor digitorum longus muscle (63). These different responses to insulin 
between two skeletal muscles may reflect differences in insulin sensitivity 
between a muscle of predominantly red fibers (i.e., soleus) and a muscle of 
predominately white fibers (i.e., extensor digitorum longus). Furthermore, the 
effects of starvation (i.e., low insulin levels) on protein synthesis (63) and 
degradation (63, 86) are greater in a muscle with predominantly white fibers than 
a muscle with mostly red fibers.
All of the studies cited (32, 59, 60, 63, 64, 66, 77, 86, 87, 107, 139) have 
found insulin to have profound effects on protein metabolism and/or cellular
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growth. Furthermore, several studies (60, 63, 86, 87, 139) have demonstrated 
different insulin sensitivities for muscles that are comprised of mostly red fibers 
versus those that are comprised of mostly white fibers or are of mixed fiber 
distribution.
The exact mechanism whereby Cr potentiates insulin action has not yet 
been elucidated. Theories of Cr action have included inhibition of tissue 
insulinase (113), enhanced insulin binding to the receptor (113, 118), and 
increased production or membrane insertion rate of the insulin receptor (3, 51). 
Mertz and Roginski (118) used D-galactose as a substrate to examine the effects 
of Cr and insulin upon cellular uptake. D-galactose was chosen because its 
cellular entry is regulated by insulin but it is not readily metabolized by peripheral 
tissue. It was found that the uptake of D-galactose in epididymal fat tissue in the 
presence of both Cr and insulin was almost immediate. These results would 
probably preclude Cr as an insulinase inhibitor or a facilitator of insulin receptor 
production. It was suggested that Cr may be an essential cofactor for insulin 
(118).
Several studies support the hypothesis that Cr may facilitate the initial 
interaction between insulin and the receptor (29, 36, 55, 61). Insulin may be 
bound to tissues by means of a disulfide bond (29, 61), presumably resulting 
from a thiol-disulfide interchange reaction between a receptor sulfhydryl group 
and a disulfide bond in insulin (29). Chromium may form a ternary complex with 
insulin and the receptor, and Mertz (116) has described a model whereby Cr is
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involved in sulfhydryl-disulfide linkages between insulin and its receptor. 
Polarographic data support this model and have shown that Cr forms linkages 
with sulfur groups of insulin in the membrane of mitochondria (36). Furthermore, 
insulin has been shown to interact with the membrane through sulfhydryl- 
disulfide linkages, and this is enhanced by the presence of Cr (36).
However, two recent studies (3, 51) have suggested that Cr may also 
potentiate insulin action by increasing production or membrane insertion rate of 
the insulin receptor. Evans and Bowman (51) examined glucose and L-leucine 
uptake in the rat myoblast after incubating the cells for three days in media 
containing various Cr compounds. They found that the potentiation of insulin 
upon cellular uptake of these substrates occurred only after the cells had been 
incubated in a media containing Cr as CrPic, but not as CrNic or CrCI3. 
However, when the cells were not previously incubated in CrPic, but it was later 
added in the presence of insulin, potentiation was not seen. Therefore, CrPic did 
not appear to have a direct effect upon the insulin-insulin receptor binding. It 
was also found that the quantity of insulin that was initially bound to the cells 
was greatest for those preincubated in CrPic, suggesting an increase in receptor 
number (51). In a preliminary study, Hasten and Keenan (79) reproduced these 
results for cellular uptake of L-leucine, but they also examined the effects of 
Brewer’s yeast. It was found that Brewer’s yeast and CrPic were equivalent in 
potentiating the uptake of L-leucine in the skeletal muscle assay, but that CrNic 
and CrCI3 were less effective. As before (51), for enhancement of L-leucine
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uptake, the cells had to be preincubated in media containing CrPic or Brewer’s 
yeast rather than simply adding these Cr-containing compounds during the 
assay procedure.
In the study of Evans and Bowman (51), it appeared that receptor number 
was greater in cells previously grown in CrPic than cells precultured in CrNic or 
CrCI3. It was concluded that CrPic may act by enhancing the synthesis and/or 
insertion rate of the insulin receptor into the cell membrane. Insulin, like some 
growth factors, undergoes ligand-induced internalization (21). The lipophilic 
nature of CrPic may increase membrane fluidity, which would increase the rate 
of internalization of the insulin-insulin receptor complex (51). However, an 
increase in membrane fluidity was not seen for inorganic Cr and only to a limited 
degree for CrNic (51).
This hypothesis is supported by the finding that insulin binding to red 
blood cells was reduced after consumption of high sucrose diets (144). This 
effect appeared to be due to a decrease in the insulin receptor number. 
Therefore, the loss of Cr that occurs in response to a high glucose (14) or 
sucrose consumption (94, 156) could have been responsible for this decrease. 
Furthermore, CrCI3 supplementation in female hypoglycemic patients was found 
to increase percent binding of insulin to red blood cells and to increase the 
number of insulin receptors (10).
Perhaps the form of Cr or the tissue type determines the mode of action. 
When insulin was previously reacted with Brewer’s yeast extract, a greater
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uptake of glucose by epididymal fat pad tissue was seen than by insulin alone 
(55). Therefore, the Cr in Brewer’s yeast may have potentiated insulin activity 
after binding to the insulin molecule. In support of this, it was found that 
Brewer’s yeast Cr binds to the a- and e-amino groups of insulin (55). In the rat 
myoblast assay, Hasten and Keenan (79) found that Brewer’s yeast, like CrPic, 
enhanced insulin action through a mechanism that occurred before the addition 
of insulin during the assay. This may have been due to an increase in the 
insulin receptor number during the incubation period (51). It is possible that the 
form of Cr in Brewer’s yeast potentiates insulin action through more than one 
mechanism. Whether or not the same can be said for other Cr complexes is 
uncertain.
2.4. CHROMIUM EFFECTS ON GLUCOSE TOLERANCE 
Mertz and Schwarz (124) found that rats fed a 30% Torula yeast diet for 
a few weeks developed a progressive impairment of glucose tolerance. Other 
investigators have confirmed this finding (122, 153, 154). After only 7 days, the 
glucose removal rate in response to a glucose tolerance test (GTT) decreased 
for rats fed a Torula yeast diet, whereas Cr-supplemented rats had an increased 
removal rate (122). Even though glucose tolerance was impaired, these Cr- 
deficient rats were not hyperglycemic nor glycosuric. However, Schroeder (153, 
154) did find increased blood and urinary glucose levels in animals raised under 
more stringent Cr-free conditions, particularly in the 3rd and 4th generations. It 
was found that this impairment could be prevented by adding Brewer’s yeast,
McCollum’s wheat-casein ration, or hospital table scraps to the diet (125). 
Furthermore, the impaired glucose tolerance of the animals could be improved 
within 18 hours by stomach tubing Brewer’s yeast fractions or any of several 
trivalent Cr complexes (125, 169). The fully developed impairment is also cured 
within 1 to 2 weeks by administering Brewer’s yeast fractions either through the 
diet (123, 125) or by intravenous injection (121). Glinsmann and Mertz (70) 
found that all improvements in glucose tolerance were related to enhanced 
uptake of glucose rather than decreased absorption or increased excretion.
A summary of studies that have examined the effects of Cr 
supplementation upon glucose metabolism is given in Table 2.1. Studies of 
inorganic Cr have given mixed results (12, 44, 54, 83, 122, 128, 145, 153, 154, 
156, 171, 183). Schroeder found that Cr acetate given in the drinking water of 
rats resulted in lower fasting blood glucose (153, 154, 156) and reduced urinary 
glucose (153, 154) levels as compared to Cr-deficient rats. However, the rat 
study of Donaldson et al. (44) found no improvements in glucose metabolism 
after CrCI3 supplementation. Although Riales and Albrink (145) found that the 
glucose tolerance of normal men was improved by CrCI3 supplementation, other 
studies of normal (12, 171), insulin dependent diabetic (IDDM) (171), and non­
insulin dependent diabetic (NIDDM) (171, 183) human subjects did not see 
significant improvements. Two additional human studies (83, 128) did observe 
improvements in glucose metabolism when high doses of CrCI3 were given. The 
glucose tolerance of malnourished infants was improved in just 18 hours after
Table 2.1. Chromium Supplementation Effects on Glucose Metabolism.
Supplement Dose Duration Subjects
Fasting
Insulin
Fasting
Glucose
GTT
Insulin
GTT
Glucose
Urinary
Glucose
Glycated
Hemoglobin Reference
Brewer’s
yeast
10.9 pg 
Cr/day 8 weeks
Human
(Elderly) 4 4 135
Brewer’s
yeast
4 pg
Cr/day 3 months
Human (Normal/ 
Hyperglycemic)
4 4 4
(Hyperglycemic) 104
Brewer’s
yeast
? (I.P. 
injection) 4 hours
Mice (Normal/ 
Diabetic) 4 181
Brewer's
yeast ?
1-2
weeks Rats 4 125
Pork
kidney ?
1-2
weeks Rats 4 125
Dark brown 
sugar ? 10 months Rats 4 156
CrPic
200 pg 
Cr/day 42 days
Human
(NIDDM) 4 50
CrPic
200 pg 
Cr/day 8 weeks
Human
(NIDDM) 4 4 48
CrPic
100-200 ppb 
Cr (feed)
73-98
days Swine N.S. N.S. 137
CrPic
1 ppm Cr 
(feed) 200 days
Rats
(Aging) 4 4 54
CrPic
370 ppb Cr 
(feed) 56 days
Growing
Calves N.S. N.S. N.S. 4 27
See text for abbreviations, 
(table con’d.)
Table 2.1. Chromium Supplementation Effects on Glucose Metabolism.
Supplement Dose Duration Subjects
Fasting
Insulin
Fasting
Glucose
GTT
Insulin
GTT
Glucose
Urinary
Glucose
Glycated
Hemoglobin Reference
CrNic
200, 800 pg 
Cr/day 8 weeks
Human {Weight­
lifting Class (M)} N.S. N.S. N.S. 99
CrNic
1 ppm Cr 
(feed) 200 days
Rats
(Aging) N.S. N.S. 54
CrNic
? (I.V., feed, 
stomach tube) ? Rats 1 1 115, 117
CrNic- 
amino adds
? (I.P. 
injection)
30-60
minutes
Mice (Normal/ 
Diabetic) I 181
CrCI3
100 pg 
Cr/day 12 weeks Human (M) i I I 145
CrCI3
200 pg 
Cr/day 12 weeks Human N.S. N.S. N.S. 12
CrCI3
200 pg 
Cr/day 6 weeks
- Human 
(NIDDM) N.S. N.S. N.S. N.S. 183
CrCI3
150 pg 
Cr/day 16 weeks
Human (Normal/ 
IDDM/NIDDM) N.S. N.S. 171
CrCI3
600 pg 
Cr/day
2-4
months
Human (IDDM/ 
NIDDM) 128
CrCI3
250 pg 
Cr/day 18 hours
Human (Malnour­
ished Infants) 1 83
CrCI3
1 ppm Cr 
(feed) 200 days
Rats
(Aging) N.S. N.S. 54
(table con’d.)
Table 2.1. Chromium Supplementation Effects on Glucose Metabolism.
Supplement Dose Duration Subjects
Fasting
Insulin
Fasting
Glucose
GTT
Insulin
GTT
Glucose
Urinary
Glucose
Glycated
Hemoglobin Reference
CrCI3
5 ppm Cr 
(water) 1 week Rats i 122
CrCI3
2 ppm Cr 
(water) 18 months Rats N.S. N.S. 44
Cr acetate
5 ppm Cr 
(water) 10 months Rats
i
(F) 156
Cr acetate
2 or 5 ppm Cr 
(water)
300 days 
to life Rats 153, 154
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the administration of 250 jug Cr (83), and fasting glucose levels of both IDDM and 
NIDDM human subjects decreased after receiving 600 / jg Cr/day for 2-4 months 
(128). These studies support the contention of Glinsmann and Mertz (70), that 
the improvement of glucose tolerance is dose related and due to considerable 
individual variation. Additionally, the initial Cr status of these subjects may have 
been compromised, since one study (83) was of severely malnourished infants 
and the other (128) was of diabetic (IDDM and NIDDM) patients. Furthermore, 
the four rat studies (122, 153, 154, 156) that observed improvements in glucose 
tolerance were based on animals that were raised under fairly stringent Cr- 
deficient conditions. This may indicate that the Cr and overall nutritional status 
plays a part in the subjects’ response to Cr supplementation.
Studies using Brewer’s yeast extracts have consistently produced more 
positive results than studies using inorganic forms of Cr. Liu and Morris (104) 
gave 12 hyperglycemic and 15 control women 4 / jg Cr as Brewer’s yeast extract 
daily for 3 months. Both groups showed decreased serum glucose and insulin 
levels after supplementation. Similarly, Offenbacher and Pi-Sunyer (135) 
observed that 10.8 jug Cr/day as Brewer’s yeast improved the glucose tolerance 
and insulin sensitivity of elderly subjects. In these two human studies, relatively 
small doses of Cr were effective in improving glucose tolerance. This supports 
the observation that compared to simple Cr compounds, much smaller amounts 
of Cr as GTF are needed to improve the impaired glucose tolerance of Cr- 
deficient rats (113, 179). Several human and animal studies that have examined
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Brewer’s yeast or other naturally occurring forms of Cr have reported reductions 
in fasting blood glucose levels (104, 156) or improvements in glucose tolerance 
(104, 125, 135, 181).
For CrNic supplementation, Evans and Pouchnik (54) did not observe 
decreased fasting blood glucose levels in aging rats, and Lefavi et al. (99) did 
not observe any improvement in glucose tolerance in young male weight lifting 
students. However, it has been reported that CrNic complexes improve the 
glucose tolerance of rats when added to the diet or given by stomach tube 
(117), and when given by intravenous injection (115, 117). Tuman et al. (181) 
found that intraperitoneal injections of CrNic-amino acid complexes decreased 
blood glucose levels in both normal and genetically diabetic rats. Furthermore, 
these complexes were effective in only 30 to 60 minutes as compared to 4 hours 
for the Brewer’s yeast extract. However, the degree to which blood glucose was 
ultimately reduced was greater for Brewer’s yeast (29 to 36%) than for CrNic- 
amino acid complexes (15 to 20%). These authors concluded that the synthetic 
CrNic-amino acid complexes were similar to, but not identical with, the GTF 
extract from Brewer’s yeast (181).
Chromium in the form of CrPic has also yielded positive results. In 
NIDDM subjects that were given 200 n g Cr as CrPic for 6 weeks, fasting blood 
glucose levels decreased significantly (48). Additionally, Evans and Pouchnik 
(54) found that CrPic decreased serum glucose levels in aging rats, whereas 
equivalent doses of Cr as CrCI3 or CrNic were ineffective. Furthermore, a
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marked decrease in blood glucose levels of NIDDM Native Americans was seen 
after only 2 weeks of supplementation with 200 ng  Cr as CrPic (50). However, 
two animal studies did not observe any changes in resting blood glucose or 
insulin levels after CrPic supplementation for 10 to 14 weeks in the swine (137) 
or for 8 weeks in the calf (27), although the glucose clearance rates in response 
to an intravenous GTT were increased in the calf (27).
Rabinowitz et al. (143) found that the mean tissue and body fluid levels 
of Cr were similar between normal and diabetic (IDDM and NIDDM) men. 
However, the lowest Cr levels in hair and erythrocytes were seen in a few 
individual diabetics, suggesting that a certain subgroup may be Cr deficient. 
Furthermore, the urinary Cr output of the diabetic (IDDM and NIDDM) men was 
approximately 63% greater than that of the normal men, although the difference 
did not reach significance (143). This supports the previous finding of 
Vanderlinde et al. (185) that IDDM patients excrete approximately three times as 
much Cr in the urine as normal subjects. This increase in urinary Cr loss may 
predispose some diabetics to Cr deficiencies (3). Since there are many possible 
causes of glucose intolerance, Cr supplementation can only be expected to 
improve those cases that are caused by a Cr deficiency (112). Therefore, the 
Cr status of the subjects as well as the form of Cr supplementation probably 
plays a part in the degree to which glucose metabolism is improved. Since Cr 
and probably other elements in physiologic doses have no pharmacologic 
action, but only restore deficient functions to normal (69), the apparent effect
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depends on the degree of the deficiency. The more severe the deficiency, the 
more profound will be the observed impairment and the effects of 
resupplementation (122).
Decreased blood glucose levels may also reduce the rate of glycosylation 
in the body. Glycosylation is a nonenzymatic reaction in the body between 
glucose and proteins into Advanced Glycosylation End products (AGE’s). These 
AGE’s are yellowish brown substances, and they are able to cross-link adjacent 
proteins (33, 163). It has been found that diabetics (IDDM and NIDDM), due to 
elevated blood glucose levels, have higher than normal levels of glycated 
hemoglobin (33, 190). Complications of diabetes that may be due to the 
glycosylation process include cataracts, glomerolpathy, and atherosclerosis 
(163). This may also account for the necrotic liver degeneration associated with 
impaired glucose tolerance in the rat (124).
It is conceivable that the slow accumulation of AGE’s could underlie many 
of the changes that are associated with aging (108, 190). This hypothesis was 
advanced by Masoro et al. (108) by demonstrating that the food restriction of 
rats, which is thought to retard the aging process, resulted in lower blood 
glucose and glycated hemoglobin levels than that of ad libitum fed rats. 
Therefore, Cr supplementation may not only prevent the complications of 
hyperglycemia, but it may partially explain the increased longevity seen in 
rodents whose diet has been supplemented with Cr (52, 53, 119, 159, 160, 161, 
162).
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Chromium supplementation in the form of CrPic has been shown to lower 
fasting glycated hemoglobin levels in NIDDM humans (48) and aging rats (54). 
However, in the rat, equivalent doses of Cr as CrCI3 or CrNic were ineffective in 
reducing levels of glycated hemoglobin (54). Another study (183) also found 
that 200 jug Cr/day as CrCI3 was ineffective in reducing glycated hemoglobin 
levels in NIDDM human subjects. However, the number of studies that have 
examined glycated hemoglobin levels is limited, so no definite conclusion about 
the effects of Cr supplementation can be made at this point.
2.5. CHROMIUM EFFECTS ON ANABOLISM AND BODY COMPOSITION 
Most of the research in the past has examined the interaction of Cr and 
insulin in regard to glucose and lipid metabolism. However, insulin also has a 
key role in muscle metabolism (57, 71). Insulin has been shown to increase 
glucose and amino acid uptake into muscle cells (81), activate ribosomal 
translational activity (81), and enhance the actions of growth hormone (72). 
Additionally, insulin inhibits enzymes that catabolize amino acids and protein 
(57). Together these factors may cause increased anabolic and decreased 
catabolic processes in the muscle cell. Furthermore, insulin increases the 
activity of muscle glycogen synthase (22), thereby enhancing glucose storage 
as well as uptake (92). Therefore, any increases in lean body mass that may 
take place due to Cr supplementation could be due to increases in muscle 
protein and/or glycogen content.
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It has also been found that Cr supplementation may reduce body fat (48, 
88, 137). Although the anabolic effects of Cr may be expected due to its 
interaction with insulin, the decrease in body fat is harder to explain, since insulin 
also increases uptake of fatty acids by adipose tissue, increases lipogenesis in 
the liver and in adipose tissue, and inhibits fatty acid oxidation in the liver (76, 
189). However, Cr may stimulate dietary-induced thermogenesis by promoting 
hypothalamic insulin-mediated activation of the sympathetic nervous system (58, 
111, 150, 151). A large proportion of dietary-induced thermogenesis, at least in 
laboratory rodents, is due to sympathetic release of norepinephrine, which 
activates uncoupling of oxidative phosphorylation in brown adipose tissue (151). 
In support of centrally-induced thermogenesis, insulin receptors and insulin- 
dependent glucoreceptors have been identified within the hypothalamus (37, 
191), and the ventromedial hypothalamus activates sympathetic outflow to brown 
adipose tissue (134, 140, 152). Furthermore, ciglitazone, a drug that improves 
insulin sensitivity, has been shown to enhance thermogenesis via sympathetic 
activation of brown adipose tissue (152). This thermogenic effect in response 
to catecholamine release has been termed "facultative" thermogenesis, whereas 
"obligatory" thermogenesis is accounted for by glucose uptake and glycogen 
synthesis (16). It is facultative thermogenesis that is most likely enhanced by 
CrPic supplementation (111, 191).
Although the origin of brain insulin has been questioned, there is recent 
evidence that peripheral insulin of pancreatic origin is delivered to the brain
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through receptor-mediated, transendothelial transport (165). Since conditions 
which cause insulin resistance may reduce transendothelial insulin transport 
(165), Cr potentiation at the blood-brain barrier could enhance insulin delivery 
to the brain. Due to its lipid solubility, CrPic may be more efficient than other 
forms of Cr in crossing the blood-brain barrier (111). It is also possible that Cr 
enhances the uptake of insulin by insulin binding proteins in the brain 
endothelium (166).
In addition to thermogenesis, centrally administered insulin has been 
found to suppress feed intake in rats (25). This reduction in feed intake 
suggests that insulin may act centrally as a satiety signal for weight reduction 
(191). Since central injections of insulin suppress feed intake and body weight 
in normal animals (25, 151, 192), it is possible that Cr supplementation may 
potentiate these effects. Peripherally administered insulin also acts to decrease 
feed intake and increase dietary-induced thermogenesis, as long as 
hypoglycemia is avoided (165). Furthermore, insulin acts to inhibit hypothalamic 
production of neuropeptide Y, a brain neuropeptide that stimulates feeding, via 
insulin receptors in the arcuate nucleus of the hypothalamus (91, 164). Again, 
Cr potentiation of these insulin actions would act to suppress feed intake. The 
diet composition may play an important part in the ability of insulin to reduce 
food intake. Whereas rats on a high carbohydrate diet decreased feed 
consumption in response to centrally administered insulin, no effect was seen 
when rats were given a diet high in fat (15). This finding is consistent with
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insulin’s effect on neuropeptide Y synthesis, since neuropeptide Y causes a 
selective increase in dietary carbohydrate intake (165).
Additionally, in cases of high circulating levels of insulin, muscle tissue is 
more insulin-resistant than adipose tissue (18). In such a case, the 
enhancement of insulin sensitivity of muscle by Cr supplementation could reduce 
the stimulus for fat production by reducing circulating levels of insulin. 
Furthermore, Cr potentiation of insulin could play a permissive role in growth 
hormone action through the generation of somatomedin by the liver (72). This 
could lead to reductions in body fat as well as increases in lean body mass, 
since growth hormone stimulates lipolysis and protein synthesis (76).
The combination of low Cr intakes (8, 97) and increased urinary losses of 
Cr due to exercise (5, 7, 9, 13, 30) may predispose athletes to a marginal Cr 
status (80, 100). Therefore, it has been suggested that if athletes are given Cr 
in a bioavailable form, they may experience an increase in strength and/or 
muscle mass with a concurrent reduction in body fat in excess of that due to 
training alone (48, 80). In response to these suggestions, synthetic Cr 
supplements, particularly CrNic and CrPic, have recently appeared in the health 
and fitness market (188). In a recent review article, Lefavi et al. (100) stated that 
any possible anabolic effects of Cr supplementation in athletes would likely be 
marginal and would probably occur only after a relatively long period of time. 
Furthermore, they emphasized that Cr is a nutrient rather than a drug, and that 
anabolic steroid-like muscle mass increases should not be expected. However,
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considering the low toxicity of Cr (112) and the possibility of a marginal Cr status 
in athletes (80, 100), supplementation with a bioavailable form of Cr would seem 
to be reasonable, particularly when one considers that the difference between 
winning and losing in athletic competition is often small as well.
A summary of studies that have examined the effects of Cr 
supplementation upon body composition is given in Table 2.2. Both human and 
animal studies have indicated that Cr supplementation enhances the 
development of lean body mass (48, 54, 78, 88, 93, 102, 119, 137). However, 
all but one (119) of these studies have used Cr in the form of CrPic. Two 
studies (54, 98) that used Cr as CrNic failed to observe any changes in lean 
body mass. However, Mertz and Roginski (117) have reported that oral 
ingestion of Cr as CrNic did increase the body weight of rats as compared to the 
Cr-deficient state. Several animal studies (44, 119,153, 154,161, 162,174, 175) 
that have used CrCI3 or Cr acetate have observed increased growth rates. 
However, only one (119) of these studies analyzed the tissues to observe a 
concurrent increase in lean body mass.
Three studies that found significant body composition changes in weight 
training volunteers (48, 80) and football players (48) used 200 /ig  Cr as CrPic. 
Evans (48) found that males in a weight training class had significant increases 
in body weight, lean body mass, and calf circumference after CrPic 
supplementation. Hasten et al. (80) found that female weight training students 
experienced a significant increase in body weight, although the same increase
Table 2.2. Chromium Supplementation Effects on Body Composition.
Supplement Dose Duration Subjects BW LBM %BF
Circum­
ferences Reference
Brewer's
Yeast
400 ppb Cr 
(feed) 28 days
Market-transit 
Stressed Calves N.S. 34
CrPic
200 pg 
Cr/day 6 weeks
Human {Football 
Players (M)} N.S. t i N.S. 48
CrPic
200 pg 
Cr/day 40 days
Human {Weightlifting 
Class (M)} t t N.S. t 48
CrPic
200 pg 
Cr/day 12 weeks
Human (Weightlifing 
Class)
T(F)
N.S. (M) N.S. N.S. N.S. 80
CrPic
200,400 pg 
Cr/day 12 weeks
Human (Aerobics 
Class) t 54
CrPic
200, 400 pg 
Cr/day 72 days
Human (Middle- 
aged/Elderly) t i 88
CrPic
100, 200 ppb 
Cr (feed) 73-98 days Swine N.S. t i 137
CrPic
300 ppb Cr 
(feed) 12 weeks
Rats (Running/ 
Sedentary) N.S. t N.S. 78
CrPic
300 ppb Cr 
(feed) 6 weeks Swine N.S. N.S. N.S. 56
See text for abbreviations, 
(table con’d.)
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Table 2.2. Chromium Supplementation Effects on Body Composition.
Supplement Dose Duration Subjects BW LBM %BF
Circum­
ferences Reference
CrPic
100, 200, 1,000 
ppb Cr (feed) ? Swine t 102
CrPic
250 ppb Cr 
(feed) 85 days Lamb N.S. t I 93
CrNic
200, 800 pg 
Cr/day 8 weeks
Human {Weightlifting 
Class (M)} N.S. N.S. N.S. 98
CrNic
200, 400 pg 
Cr/day 12 weeks
Human (Aerobics 
Class) N.S. 54
CrNic ? ? Rats t 117
O o c*>
200 pg 
Cr/day 12 weeks Human (M) 1 145
CrCI3
200 pg 
Cr/day 12 weeks Human N.S. 12
CrCI3
250 pg 
Cr/day 30 days
Human (Marasmic 
Infants) t 75
CrCI3
2 ppm Cr 
(water) 12 weeks
Rats (Low-Protein 
Diet) t t 119
(table con’d.)
Table 2.2. Chromium Supplementation Effects on Body Composition.
Supplement Dose Duration Subjects BW LBM %BF
Circum­
ferences Reference
CrCi3
20, 40, 80 
ppm Cr (feed) 14 days
Turkeys 
(1 week old) t 175
CrCI3
200 ppb Cr 
(feed) 98 days Swine N.S. N.S. N.S. 137
CrCI3 or 
Cr acetate
2 or 5 ppm 
Cr (water)
18 months 
to life Rats, Mice t 44,153,154161,162
CrCI3 or 
Cr acetate
10 ppm Cr 
(water) 22 weeks
Squirrel
Monkeys N.S. 40
Cr citrate
1 ppm Cr 
(feed) 16 weeks Rats N.S. 31
CrCI3
10,000, 100,000 
ppb Cr (feed) ? Swine t 174
CrCI3
30,000, 60,000 
ppb Cr (feed) ? Swine N.S. N.S. N.S. 138
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was not seen for the male participants. In a group of football players (48), the 
increase in lean body mass was offset by a decrease in percent body fat, with 
no significant increase in body weight.
Evans and Pouchnik (54) examined the effects of both CrPic and CrNic 
on students enrolled in an aerobics class. The women were given 200 jug Cr 
whereas the men received 400 jug Cr in either form. Both males and females 
who received Cr as CrPic, but not as CrNic, had significant increases in lean 
body mass. In a study of male weight lifters consuming CrNic supplements of 
200 and 800 jug Cr/day, Lefavi et al. (98) also failed to observe any significant 
body composition changes.
In a crossover study of adults who were not involved in any formal 
exercise program and who were given 200 and 400 jug Cr as CrPic (88), there 
was a significant increase in lean body mass with a decrease in percent body 
fat while ingesting the supplement. These body composition changes were 
slightly greater for 400 versus 200 jug, but not significantly so.
With one exception (56), animal studies that have examined CrPic 
supplementation have also shown favorable body composition changes (78, 93, 
102, 137). Hasten et al. (78) found that both skeletal and cardiac muscle mass 
were increased 13 to 22% in rats that had 300 ppb Cr as CrPic added to a basal 
cornmeal-casein diet. Similarly, Kitchalong et al. (93) found that the addition of 
250 ppb Cr as CrPic to a corn-cottonseed hull-based diet increased cardiac and 
overall lean body mass in the lamb. Evock-Clover et al. (56) found that 300 ppb
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Cr as CrPic in the diet of swine had no effect on most organ weights except for 
an 8% increase in weight of the heart. Furthermore, Roginski and Mertz (147) 
found that amino acid uptake into the heart was greater in rats whose water was 
supplemented with 2 ppm Cr as CrCI3. Therefore, Cr supplementation may 
increase cardiac as well as skeletal muscle mass.
Lindemann et al. (102) found an increase in loin eye area and a 
concurrent decrease in tenth rib fat in the swine for CrPic additions to the feed 
at 100, 200, and 1000 ppb Cr. Except for erratic results at the 500 ppb level, 
these effects were greater with increasing dosage. Likewise, Page et al. (137) 
found that the addition of 100 or 200 ppb Cr as CrPic to a basal corn-soybean 
diet that contained 735 ppb of endogenous Cr increased the loin eye area by 
18%, the percentage of muscling by 7%, and decreased the tenth rib fat by 21 % 
in the swine. However, 200 ppb Cr as CrCI3 did not produce these changes, 
even when given in the combination of CrCI3 and picolinate. Furthermore, a 
previous study by Page et al. (138) found that 30,000 and 60,000 ppb Cr as 
CrCI3 did not affect carcass traits in the swine. Therefore, even at very high 
dosages, inorganic Cr supplementation did not appear to improve body 
composition. This supports Evans’ hypothesis that the bioavailability and/or 
bioactivity of Cr is greater when it is complexed to picolinate (47).
Although all studies that have observed changes in lean body mass were 
increases, such was not the case for body weight. For CrPic, two human studies 
(48, 80) found increases in body weight. However, Evans (48) found that body
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weight in football players did not change even though an increase in lean body 
mass was seen. In this case (48) as well as in another human study (88), a 
concurrent decrease in body fat was seen. Three other animal studies (56, 78, 
93) of CrPic supplementation did not report significant changes in body weight, 
although body composition changes were reported in two cases (78, 93).
Whereas one study (12) of CrCI3 supplementation in adult men and 
women reported no change in body weight, another study (145) of adult men 
observed a mean decrease. However, body composition analyses were not 
conducted in either case (12, 145). In another human study, it was found that 
marasmic infants who were given a supplement of 250 pg Cr/day as CrCI3 
gained more body weight than the control group in a 30 day period (75). Most 
animal studies (44, 119, 153, 154, 161, 162, 174, 175) of inorganic Cr have also 
found increases in body weight, although four studies (31, 40, 137, 138) did not 
observe any significant changes. Though only one of these studies that noticed 
body weight changes conducted organ analyses to determine lean body mass 
changes (119), it was concluded that increases in growth were accompanied by 
at least proportional increases in tissue protein. However, Page et al. (137, 138) 
did not observe any body weight or body composition changes due to CrCI3 
supplementation in the swine.
One study that examined the effects of Brewer’s yeast supplementation 
on market-transit stressed calves (34) did not see an increase in body weight, 
but did observe a decrease in production of cortisol, a hormone that is
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antagonistic to the actions of insulin (76). Additionally, lambs fed a daily 
molasses ash supplement containing 37 /jg  Cr or an equivalent dose as CrCI3, 
had an increased nitrogen utilization (26). Therefore, both inorganic Cr and a 
naturally occurring form of Cr in the molasses may have enhanced protein 
synthesis and/or decreased protein catabolism.
Although body composition changes due to Cr supplementation have 
been reported, no significant changes in strength as measured by the one- 
repetition maximum for the bench press or the squat were found for either CrNic 
(98) or CrPic (80). However, the study that used CrNic (98) did not report any 
changes in body composition, either. Furthermore, the study that used CrPic 
(80) did notice larger improvements in strength for the female supplementation 
group that gained more body weight than the female placebo group, although 
the strength measurements did not reach the level of significance. Therefore, a 
statement concluding the possible effects of Cr supplementation upon strength 
cannot be made at this time.
Since muscles of different fiber types have been shown to have varying 
degrees of insulin sensitivity (60, 63, 86, 87, 139), it is possible that the effects 
of Cr supplementation may vary according to the fiber type. An in vitro study 
(63) has shown that insulin in physiological levels causes a greater reduction in 
protein catabolism in muscles of predominantly white versus red fibers. Both in 
vitro (86, 87) and in vivo (60, 139) studies have shown that insulin deficiency 
impairs protein synthesis to a greater degree in muscles with a mixed fiber
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composition compared to those with more red fibers. Additionally, low insulin 
levels in vivo have greater effects on both protein synthesis (86) and degradation 
(63, 86) in muscles with more white than red fibers. Furthermore, CrCI3 
supplementation in the turkey hen significantly increased the Cr content in the 
breast but not in the leg (6). Since the breast is comprised of mostly white fibers 
and the leg muscles contain mostly red fibers, it appears that Cr may 
accumulate to a greater degree in muscles that have greater insulin sensitivities.
After CrPic supplementation in the rat, however, Hasten et al. (78) found 
an increase in wet weight for both muscles of predominantly red fiber (i.e., 
soleus) and mixed-fiber (i.e., gastrocnemius) types. Further work should 
examine possible effects of Cr supplementation upon muscles of different fiber 
compositions.
2.6. CHROMIUM EFFECTS ON GROWTH RATE. DAILY FEED INTAKE.
AND FEED EFFICIENCY 
Several studies of Cr deficiency have documented decreased growth rates 
in rats and mice (119, 153, 154, 161, 162). In these studies, very low levels of 
dietary Cr were given (100-200 ppb), and very stringent laboratory conditions 
such as plastic cages with glass grids and filtered air were maintained. When 
2,000 or 5,000 ppb Cr as CrCI3 or Cr acetate were added to the drinking water 
of these animals, increases in body weight were seen. These increases due to 
Cr intake were seen in both sexes (153,154,161,162), although one study (162) 
found that the Cr addition enhanced the growth rate of females to a greater
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degree than that of the males. The higher dosage of 5,000 ppb did not appear 
to yield better results than the 2,000 ppb level (154, 162). Schroeder et al. found 
that the growth curves of Cr-sufficient and Cr-deficient weanling mice diverged 
at 80 to 100 days of age (161) and that Cr-supplemented rats weighed 26 
percent more than Cr-deficient rats at 90 days of age (153). Two other studies 
by Schroeder et al. found that the mean differences between weight of Cr- 
sufficient and Cr-deficient rats were statistically significant at 2, 6, and 12 months 
(162), but the proportionate retardation of growth appeared to be greatest at 
young ages (154).
Several recent studies (27, 34, 56, 93, 102, 137, 138, 174, 175) have 
examined the effects of Cr supplementation on growth rate (expressed as 
average daily gain, ADG), daily feed intake (DFI), and feed efficiency (FE) in the 
animal industry. A summary of these studies is given in Table 2.3. For changes 
in ADG, four studies (34, 137, 174, 175) reported increases, one study (137) 
found a decrease, and the rest (27, 34, 56, 93, 102, 137, 138) reported no 
changes. Chang and Mowat (34) found that the addition of 400 ppb Cr as high­
e r yeast to the feed of market-transit stressed calves increased ADG, mainly due 
to an increase in DFI for the first three weeks. After four weeks, the addition of 
200 ppb Cr as high-Cr yeast no longer had an effect on ADG (34). The addition 
of 25, 50, 100, and 200 ppb Cr as CrPic caused a mainly linear increase in ADG 
in growing-finishing pigs (137). However, higher concentrations of 400 and 800 
ppb caused a decrease in ADG, mainly due to a decrease in DFI (137). Steele
Table 2.3. Chromium Supplementation Effects on Growth and Feed Characteristics.
Supplement Dose Duration Subjects ADG DFI FE Reference
High-Cr
Yeast
400 ppb Cr 
(feed) 28 days
Market-transit 
Stressed Calves f f f 34
High-Cr
Yeast
200 ppb Cr 
(feed) 70 days
Growing
Calves N.S. N.S. N.S. 34
CrPic
25, 50, 100, 
200 ppb Cr 
(feed) 73 days Swine f N.S. N.S. 137
CrPic
100, 200, 400, 
800 ppb Cr 
(feed) 83 days Swine 1 i N.S. 137
CrPic
100, 200 ppb 
Cr (feed) 98 days Swine N.S. t 137
CrPic
250 ppb 
Cr (feed) 85 days Lambs N.S. N.S. 93
CrPic
100, 200, 500, 
1000 ppb Cr 
(feed) ? Swine N.S. N.S. N.S. 102
See text for abbreviations, 
(table con’d.)
Table 2.3. Chromium Supplementation Effects on Growth and Feed Characteristics.
Supplement Dose Duration Subjects ADG DFI FE Reference
CrPic
300 ppb Cr 
(feed) 6 weeks Swine N.S. N.S. N.S. 56
CrPic
370 ppb Cr 
(feed) 56 days
Growing
Calves N.S. N.S. N.S. 27
CrCI3
100, 200 ppb 
Cr (feed) 98 days Swine N.S. f 137
CrCI3
30,000, 60,000 
ppb Cr (feed) ? Swine N.S. N.S. N.S. 138
CrCI3
10,000, 100,000 
ppb Cr (feed) ? Swine t f 174
CrCI3
20,000, 40,000, 
80,000 ppb Cr 
(feed) 14 days
Turkeys 
(1 week old) t 175
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et al. found that very high dosages of CrCI3 (between 10,000 and 100,000 ppb 
Cr) increased ADG in swine (174) and in turkey poults (175).
Other animal studies of CrPic in dosages ranging from 100 to 1000 ppb 
Cr failed to observe any significant effects on ADG (27, 56, 93, 102, 137). 
Likewise, two other studies of CrCI3 supplementation in both low dosages of 100 
to 200 ppb Cr (137) and high dosages of 30,000 to 60,000 ppb Cr (138) failed 
to elicit changes in ADG. Therefore, the effects of Cr additions to animal feed 
upon growth rate appears to be highly variable.
Of the studies that reported the effects of chromium supplementation 
upon DFI (27, 34, 56, 93, 102, 137,138), two (34, 137) reported an increase and 
one (137) reported a decrease. For the market-transit stressed calves (34), the 
addition of 400 ppb Cr as high-Cr yeast increased DFI for the first three weeks. 
Furthermore, the Cr addition increased the FE, indicating that the growth rate per 
unit of feed consumption was enhanced. Feed intake also increased in swine 
for the additions of 100 to 200 ppb Cr as CrPic to the diet (137). However, 
there was no concurrent change in ADG. Furthermore, higher additions of 
CrPic (400 to 800 ppb Cr) decreased DFI, resulting in a decreased ADG. 
Therefore, FE remained unchanged.
Chromium supplementation as CrCI3 enhanced FE in two studies (137, 
174), although DFI was not reported. One of these studies was of low dosages 
(100-200 ppb Cr), and did not report any concurrent change in ADG (137). The
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other study, however, involved higher dosages (10,000-100,000 ppb Cr), and 
reported an increase in ADG as well as FE (174).
Other studies of high-Cr yeast (34), CrPic (27, 56, 93,102,137), and CrCI3 
(138) supplementation did not report any significant changes in feedlot 
performance. Therefore, as with ADG, the effects of Cr supplementation upon 
DFI and FE vary greatly.
Three studies (93, 102, 137) observed body composition changes due to 
CrPic supplementation in the absence of any alterations in DFI or FE. Therefore, 
these changes appeared to occur due to the effects of Cr on metabolism rather 
than on changes in feed consumption or utilization.
Glucose intolerance is considered to be a symptom of marginal Cr 
deficiency, with decreased growth seen only in more pronounced cases of 
deficiency (119, 122). Although an impairment in growth in the rodent is usually 
seen only under stringent Cr-free conditions (119, 153, 154, 161, 162), some 
recent animal studies (78, 93, 102, 137) have documented increases in lean 
body mass due to CrPic supplementation under normal laboratory and living 
conditions. Although changes in body composition were observed, none of 
these studies reported a treatment effect on the final body weight of the animals. 
Furthermore, none of the basal diets were overtly deficient in Cr, and Page et al. 
(137) did not observe any statistical differences in resting glucose levels between 
treatment groups in the swine even though body composition changes were 
evident. Conversely, one animal study (27) did not report any changes in body
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composition although increased glucose clearance rates were seen after 56 days 
of CrPic supplementation (370 ppb Cr) in the holstein calf. Therefore, changes 
in body composition due to Cr supplementation do not always occur 
concurrently with improvements in glucose tolerance.
CHAPTER 3. METHODS
3.1. STUDY DESIGN 
Six levels of dietary CrPic were examined in this study, and 15 rats were 
assigned to each treatment. Due to the large number of animals ( a total of 90), 
the rats arrived in three groups of 30, spaced apart in two-week intervals. These 
three groups of animals were referred to as Blocks 1, 2, and 3. Therefore, for 
each block of 30 animals, five rats were assigned to each treatment. This 
resulted in a 6 X 3 (treatment X block) study design. The data from the three 
blocks of animals were to be pooled if no significant differences were found to 
exist between blocks. However, the block effect was highly significant for several 
variables, and it was determined that a Randomized Block Design (RBD) was 
most appropriate for the data.
All animals were placed on the basal diet that contained no CrPic for four 
days after they first arrived. At this time they were randomly assigned to 
treatment but they were stratified so that mean body weight did not differ 
between treatment groups. The animals were then placed on their respective 
dietary treatments for 12 weeks. Body weight and feed consumption was 
monitored 3 days/week, on Mondays, Wednesdays, and Fridays.
On Weeks 5 and 10, ten animals from each treatment group were 
randomly chosen for body composition analyses (four rats from Block 1, three 
rats from Block 2, and three rats from Block 3). Since the three blocks arrived
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two weeks apart, these procedures, as well as all other study procedures, were 
spaced two weeks apart for each of the blocks.
On Week 11 of the study, an oral glucose tolerance test (GTT) was 
performed on the same ten rats from each treatment group that underwent body 
composition analyses.
All animals were sacrificed at the end of Week 12. In addition to body 
weight, several organ and skeletal muscle weights were recorded. If any 
differences in lean body mass or tissue weights had been found between 
treatment groups, further analyses for muscle protein, cross-sectional area, and 
glycogen content were to be conducted.
3.2. ANIMALS AND DIETARY TREATMENTS 
Ninety male Harlan Sprague-Dawley outbred weanling rats (21 days of 
age) were used in this study. The animals were divided into six treatment 
groups of 15 (five rats each from Blocks 1, 2, and 3) at 25 days of age. 
Although the initial body weights of the animals did not differ by treatment, there 
were significant block differences for initial body weight (p = 0.01), with Block 
2 having greater weights than Blocks 1 and 3 (see Appendix C.1). A follow-up 
call to representatives at Harlan Sprague-Dawley, Inc. revealed that the Block 1 
animals had originated from a breeding colony in Houston, TX (Building 211), 
whereas Blocks 2 and 3 had come from a facility in Prattville, AL (Building 218). 
The animals were kept in stainless steel housing with wire mesh flooring to allow 
urine and feces to fall through. Diets were placed in glass containers, and food
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and ultrapure water were given ad libitum. The study was conducted for 12 
weeks, and the animals were 112 to 116 days of age at sacrifice.
The basal diet that was used in this study was the AIN-76A semi-purified 
diet without the addition of Cr, the composition of which is listed in Appendix A. 
This diet has been developed to meet all the growth needs of the laboratory rat 
(1). For normal weight gain, it has been found that young rats require more than 
170 ppb dietary Cr when living under stringent Cr-deficient conditions (154). 
However, normal weight gains have been observed with 310 ppb dietary Cr 
under normal laboratory conditions with a sucrose-based diet (173). The 300 
ppb level for Cr was chosen as the median dosage level in this study since it has 
been set as the recommended level of dietary Cr for the rat (131), and since this 
level of Cr as CrPic appeared to enhance the lean body mass of the rat under 
normal laboratory conditions in a previous study (78).
The six treatments used in this study consisted of the following diets: 1) 
basal (Treatment 0); 2) basal +  75 ppb Cr as CrPic (Treatment 75); 3) basal + 
150 ppb Cr as CrPic (Treatment 150); 4) basal + 300 ppb Cr as CrPic 
(Treatment 300); 5) basal + 600 ppb Cr as CrPic (Treatment 600); and 6) basal 
+ 1500 ppb Cr as CrPic (Treatment 1500). The 1X (300 ppb), 2X (600 ppb), and 
5X (1500 ppb) levels of CrPic were examined at the request of the Federal Drug 
Administration (FDA) for approval of use in animal feed. In addition, the 0.5X 
(150 ppb) and 0.25X (75 ppb) levels were examined. The basal diets were 
analyzed for Cr content by Dr. Richard A. Anderson of the U.S.D.A. Beltsville
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Human Nutrition Resource Center (Beltsville, MD). The Cr content of eight 
random samples taken from different batches was found to be 180 (±  10) ppb.
3.3. GLUCOSE TOLERANCE 
During Week 11, ten rats from each treatment group were given an oral 
GTT. For this procedure, four rats from Block 1, three rats from Block 2, and 
three rats from Block 3 were chosen. Therefore, a total of ten rats from each 
treatment group underwent the GTT. The animals were fasted for 12 hours, and 
an initial blood sample was removed from the warmed tail. A test dose of 20 mg 
glucose/100 g BW was given by gavage as a 5% solution. Subsequent blood 
samples were then taken at 30, 45, 60, and 90 minutes. The blood was 
coagulated, spun down, and the serum was pipetted off and analyzed by the 
Trinder enzymatic procedure (Sigma #315). The glucose removal rate was 
examined by calculating the rate of glucose disappearance from the blood 
glucose peak at 30 or 45 minutes to the low level reached at 120 minutes.
Blood samples taken at sacrifice were used for the analyses of resting 
insulin and glycated hemoglobin values. For the insulin analyses, the blood 
samples were allowed to coagulate, they were spun down, and the serum was 
pipetted off and frozen for up to 6 weeks. Insulin was then assayed by means 
of the DPC Coat-a-Count Radioimmunoassay. For glycated hemoglobin, whole 
blood was collected in EDTA, and samples were assayed on the same day by 
means of the cis-diol affinity resin column procedure (Sigma #442). Due to the 
stress of the sacrifice procedure, resting glucose levels were unreliable, and the
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resting glucose values taken at Week 11 during the GTT were used instead for 
the final analyses.
A 6 X 3 (treatment X block) RBD was used to analyze the values for 
resting glucose, insulin, glycated hemoglobin, and glucose clearance.
3.4. BODY COMPOSITION 
Changes in body composition of the six treatment groups over the 12- 
week period were monitored at Weeks 5 and 10 by means of dual emission X- 
ray absorptiometry (DEXA) on the Hologic QDR°-2000 system at Pennington 
Biomedical Research Center in Baton Rouge, LA. For these analyses, the same 
rats that underwent the GTT were used (i.e., four, three, and three animals from 
Blocks 1, 2, and 3, respectively). Therefore, a total of ten rats from each 
treatment group underwent DEXA analyses. Before the procedure, the animals 
were anaesthetized with a combination of ketamine (75 mg/kg BW) and xylazine 
(25 mg/kg BW). The rat whole body scan was used to assess body weight (BW), 
lean body mass (LBM), body fat weight (FAT), and percent body fat (%BF).
A 6 X 3 (treatment X block) RBD was used to analyze each of the body 
composition variables (BW, LBM, FAT, and %BF) at both Week 5 and Week 10. 
Additionally, a 2 X 6 X 3 (time X treatment X block) RBD with repeated measures 
was conducted for each of these variables.
3.5. TISSUE WEIGHTS AND PROTEIN ANALYSES 
At the end of the 12-week treatment period, the rats were anaesthetized 
with a combination of ketamine (75 mg/kg BW) and xylazine (25 mg/kg BW).
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This procedure took place over a 3-4 day period for each block of animals. Rats 
were chosen from each treatment to be sacrificed daily between 7:00 and 10:00 
A.M.
After being anaesthetized, the animals were weighed for final BW. Then 
the soleus, plantaris, and extensor digitorum longus (EDL) muscles of both the 
right and left hindlimbs were excised, carefully trimming away any tendons. The 
wet weight of each muscle was recorded, the tissues were frozen in a container 
of isopentane that was placed in liquid nitrogen, and they were stored at -70°C 
for further analyses that may have been conducted. The left hindlimb muscles 
were also subsequently freeze-dried in order to obtain the dry weight. 
Additionally, the dry:wet weight ratios of the left hindlimb muscles were examined 
to determine water content, reflecting possible differences in muscle glycogen 
levels between the treatment groups or blocks.
The soleus, plantaris, and EDL were chosen because they consist 
predominantly of red, mixed, and white fiber types respectively (17). Although 
some plasticity of fiber types exists during the first 24 weeks of life in the rat, 
these muscles are morphologically similar to their adult state at 15 days, and no 
significant differences in overall fiber type composition exist between 12 and 24 
weeks of age (130).
After removal of the hindlimb muscles, the rats were sacrificed by 
exsanguination. The abdominal cavity was opened, and blood was drawn
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directly from the abdominal aorta. As described earlier, this blood was used for 
the analyses of resting insulin and glycated hemoglobin values.
After exsanguination, the heart, liver, kidneys, and epididymal fat pads 
were removed, weighed, frozen in liquid nitrogen, and stored at -70°C for further 
analyses. Although no treatment X block interactions or treatment effects were 
seen for any of the organ or skeletal muscle weights, preliminary protein 
analyses for the left plantaris muscle were performed.
For myofibrillar and total protein content, the dried left plantaris muscle 
was homogenized and prepared as described by Morris et al. (127). The total 
protein was then assayed with the Lowry method (106) as modified by Peterson 
(141). Myofibrillar protein content was also assessed with the Lowry method 
after isolation by differential solubility as previously described by Morris et al. 
(127).
A 6 X 3 (treatment X block) RBD was conducted for each of the tissue 
weights and relative tissue weights at sacrifice. The weights that were analyzed 
included final BW, wet weights of the right and left hindlimb muscles (soleus, 
plantaris, EDL), dry weights of the left hindlimb muscles, dry:wet weight ratios 
of the left hindlimb muscles, and wet weights of the heart (left ventricle), liver, 
kidneys, and epididymal fat pads. The relative tissue weights (g/kg BW) 
analyzed were the right and left hindlimb muscles, heart, liver, kidneys, and 
epididymal fat pads.
A 6 X 3 (treatment X block) RBD was also used to analyze the myofibrillar 
arid total protein levels, and the myofibrillar:total protein ratios for the left 
plantaris muscle.
3.6. GROWTH RATE. DAILY FEED INTAKE. AND FEED EFFICIENCY 
Body weight and feed intake were recorded 3 times/week over the 12 
weeks. Average daily gain (g/day), DFI (g/day), and FE (g BW/kg feed) were 
calculated at 2-week intervals and over the entire study period.
For these analyses, Weeks 1 and 12 were omitted due to several missing 
data points, and values were calculated for Weeks 2-3, 4-5, 6-7, 8-9, and 10-11, 
as well as the overall values for Weeks 2-11. A 6 X 3 (treatment X block) RBD 
was used to analyze the mean values of ADG, DFI, and FE for Weeks 2-11. A 
5 X 6 X 3  (time X treatment X block) RBD with repeated measures was 
conducted for these variables when broken down into 2-week intervals.
3.7. LEVEL OF SIGNIFICANT DIFFERENCES AND POST HOC ANALYSES 
The level of significant differences was set at p=0.10 a priori (62). 
Duncan’s multiple range test was conducted for any significant main effects. As 
before, the level of significance for post hoc analyses was set at p=0.10 a priori.
Further protein, cross-sectional area, and glycogen analyses for skeletal 
muscles were not carried out because no significant treatment X block 
interactions nor treatment effects were seen for wet weights, dry weights, dry:wet 
weight ratios, relative muscle weights, or overall LBM.
CHAPTER 4. RESULTS 
4.1. DATA PRESENTATION
The means for each independent variable are listed in Appendices B-E. 
As well as the overall mean, the means are given for each treatment, block, and 
treatment X block cell. Glucose tolerance data are listed in Appendix B, body 
composition data are in Appendix C, tissue weights and protein analyses data 
are in Appendix D, and growth and feed characteristics data are listed in 
Appendix E.
In this section, the glucose tolerance, body composition, and growth and 
feed characteristics data have been presented in tabular form by treatment and 
by block. Furthermore, significant interactions and main effects have been 
presented graphically.
Due to the lack of significant treatment interactions or effects, the means 
for organ and skeletal muscle wet weights and relative wet weights, as well as 
skeletal muscle dry weights and dry:wet weight ratios have been listed only by 
block. The one treatment effect that was observed has been noted at the 
bottom of the table. Since there was a significant treatment X block interaction 
for BW, this has been presented graphically. The means for the protein analyses 
have been listed by treatment and by block.
Any significant interactions for the repeated measures RBD analyses have 
been noted in the text, as well as presented graphically for the growth and feed 
intake/efficiency data.
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4.2. GLUCOSE TOLERANCE
Resting blood glucose levels (mg/dl) are listed by treatment and by block 
in Table 4.1. The treatment X block interaction was not significant, but there was 
a significant block effect, with Block 2 having higher resting glucose values than 
Block 1. This block effect can be seen in Figure 4.1. All resting blood glucose 
data are given in Appendix B.1.
Resting blood insulin levels (jjU/ml) are also listed by treatment and by 
block in Table 4.1. There were no significant treatment X block interactions, nor 
treatment or block effects, although insulin levels tended to be highest for Block 
1, followed by Block 3, and followed by Block 2 (p=0.24). All resting insulin data 
are listed in Appendix B.2.
For glycated hemoblobin, there were no significant treatment X block 
interactions nor treatment effects, but the block effect was significant. As listed 
in Table 4.1 and shown in Figure 4.2, Blocks 2 and 3 had higher glycated 
hemoglobin levels than Block 1. All glycated hemoglobin data are given in 
Appendix B.3.
There were no significant interactions, treatment or block effects for the 
GTT data (Appendix B.4). Since it was discovered after the testing that the 
animals had inadvertently received a glucose solution of 5% instead of the 
intended 50% solution, with a test dose amounting to only about one-sixth of that 
used in previous studies (124, 125), these data have not been presented in this 
section nor mentioned further in the Discussion section.
Table 4.1. Resting Blood Glucose, Insulin, and Glycated Hemoglobin (GHb) Levels at Weeks 11-12.
Treatment
0 75 150 300 600 1500
Glucose 101.04 90.22 101.99 105.58 101.01 98.00
(mg/dl) (21.43) (16.23) (13.90) (8.97) (13.76) (12.53)
Insulin 10.24 9.55 10.51 11.20 12.46 10.00
(/L/U/ml) (3.65) (2.73) (2.85) (3.87) (7.55) (2.38)
3.89 3.80 3.57 3.55 3.71 3.99
GHb (%) (•46) (-66) (-61) (.54) (-67) (-79)
Block
1 2 3
Glucose1 95.15 105.84 99.37
(mg/dl) (15.42) (13.66) (13.99)
Insulin 11.71 9.70 10.80
(//U/ml) (5.57) (3.08) (3.75)
3.52 3.87 3.85
GHb’ (%) (.93) (-39) (.39)
Values are mean ± standard deviation.
’Significant block effect, p = 0.07 for Glucose (2 > 1) and p = 0.09 for GHb (2, 3 > 1).
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Figure 4.1. Resting Blood Glucose Levels at Week 11. 
Values are mean + standard deviation. 
Significant block effect, p = 0.07 (2 > 1).
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Figure 4.2. Glycated Hemoglobin (GHb) Levels at Week 12.
Values are mean + standard deviation.
Significant block effect, p = 0.09 (2, 3 > 1).
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4.3. BODY COMPOSITION 
Body weights (g) at Weeks 5 and 10 are shown by treatment and by block 
in Tables 4.2 and 4.3, respectively. At Week 5, there were no significant 
interactions or treatment effects, but there was a significant block effect; Block 
2 was the heaviest, followed by Block 3, and followed by Block 1. This block 
effect can be seen graphically in Figure 4.3. By Week 10, there was a significant 
treatment X block interaction. As seen in Figure 4.4, this was mainly due to a 
tendency of Block 1 to decrease in BW with increasing CrPic dosage. The 
repeated measures RBD for BW revealed a time X block interaction, with a trend 
for a time X treatment X block interaction (p=0.11). This indicated that block 
was a factor in BW changes between Week 5 and Week 10, with a trend for a 
treatment effect as well, which was reflected in the BW changes seen in the 
Block 1 animals. All BW data measured through DEXA are given in Appendix 
C.2-C.3.
At both Weeks 5 and 10, the LBM (g) differences as assessed through 
DEXA were highly significant for block. As seen in Table 4.2, LBM was greatest 
for Block 2, followed by Block 3, and followed by Block 1. This same order was 
also seen at Week 10 (Table 4.3). The significant block effects for Weeks 5 and 
10 can be seen in Figures 4.5 and 4.6, respectively. The repeated measures 
RBD for LBM was significant for time X block (p=0.01), indicating that changes 
in LBM between Weeks 5 and 10 were due to block but not treatment. All LBM 
data are given in Appendix C.4-C.5.
Table 4.2. Body Weight (BW), Lean Body Mass (LBM), Fat Weight (FAT), and Percent Body Fat (%BF)
at Week 5.
Treatment
0 75 150 300 600 1500
BW (g) 295.6 288.3 299.0 298.3 294.5 298.0
(27.9) (23.4) (23.1) (22.8) (40.7) (26.5)
LBM (g) 245.8 242.3 255.0 249.4 250.2 254.3
(25.5) (19.0) (22.3) (19.2) (31.9) (18.0)
FAT2 (g) 49.9 46.0 44.0 48.9 44.3 43.8
(7.2) (8.9) (3.6) (8.4) (10.7) (10.2)
%BF2 16.9 15.9 14.8 16.4 14.9 14.5
(2.4) (2.4) (1.4) (2.3) (1.9) (2.4)
Block
1 2 3
BW’ (g) 279.0 322.4 290.9
(21.7) (22.1) (15.5)
LBM1 (g) 235.8 271.2 246.0
(19.1) (19.6) (11.4)
FAT2 (g) 43.2 51.3 44.9
(9.0) (7.0) (7.0)
%BF2 15.5 15.9 15.4
(2.8) (1.8) (1.9)
Values are mean ±  standard deviation.
'Significant block effect, p = 0.01 (2 > 3 > 1).
'Significant treatment X block interaction, p = 0.01 for FAT and p = 0.02 for %BF. 05
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Table 4.3. Body Weight (BW), Lean Body Mass (LBM), Fat Weight (FAT), and Percent Body Fat (%BF)
at Week 10.
Treatment
0 75 150 300 600 1500
BW1 (g) 393.1 377.6 391.0 387.2 383.9 386.1
(35.1) (31-1) (32.8) (36.5) (62.4) (40.4)
LBM (g) 325.8 315.7 332.6 320.3 322.9 327.6
(32.8) (27.1) (30.5) (25.6) (51.0) (29.9)
FAT1 (g) 67.3 62.0 57.6 66.9 60.9 58.5
(11.3) (14.7) (8.7) (15.9) (16.5) (15.0)
%BF1 17.2 16.4 14.8 17.2 15.8 15.0
(2.8) (3.4) (2.2) (2.7) (2.6) (2.7)
Block
1 2 3
BW' (g) 352.8 424.4 393.4
(28.8) (29.9) (16.0)
LBM2 (g) 296.5 350.8 334.3
(25.3) (27.8) (13.1)
FAT1 (g) 56.3 73.6 58.7
(11.7) (13.7) (9.7)
%BF1 15.9 17.4 14.9
(2.8) (3.0) (2.2)
Values are mean *  standard deviation.
’Significant treatment X block interaction, p = 0.07 for BW, p = 0.06 for FAT, and p = 0.09 for %BF. 
'Significant block effect, p = 0.01 (2 > 3 > 1).
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Figure 4.3. Body Weight (BW) at Week 5.
Values are mean + standard deviation. 
Significant block effect, p = 0.01 (2 > 3 > 1).
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Figure 4.4. Body Weight (BW) at Week 10.
Values are mean + standard deviation.
Significant treatment X  block interaction, p = 0.07.
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Figure 4.5. Lean Body Mass (LBM) at Week 5.
Values are mean + standard deviation. 
Significant block effect, p = 0.01 (2 > 3 > 1).
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Figure 4.6. Lean Body Mass (LBM) at Week 10.
Values are mean + standard deviation.
Significant block effect, p = 0.01 (2 > 3 >1).
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There was a significant treatment X block interaction for FAT (g) at Week 
5 and at Week 10. These data are given in Tables 4.2 and 4.3, respectively. 
Additionally, these interactions can be seen in Figures 4.7 and 4.8. At both 
Weeks 5 and 10, the main cause of the interaction was due to a decrease in FAT 
with increasing CrPic dosage for Block 1. This same effect was not seen for 
Blocks 2 and 3. The repeated measures RBD for FAT was significant for the 
interaction of time X block (p=0.01). Therefore, any changes in FAT between 
Weeks 5 and 10 were due to block. The treatment effect seen for the Block 1 
animals remained constant between the two DEXA testing sessions. All FAT 
data are given in Appendix C.6-C.7.
There were significant treatment X block interactions for %BF at Weeks 5 
and 10 (Tables 4.2 and 4.3, and Figures 4.9 and 4.10, respectively). At Week 5, 
the interaction was mainly due to a decrease in %BF with increasing CrPic 
dosage for Block 1. This same effect was evident at Week 10. These same 
trends in %BF were not seen for Blocks 2 and 3. As with FAT, the repeated 
measures RBD revealed a significant time X block interaction for %BF (p=0.01). 
Therefore, the treatment effect on %BF for the Block 1 animals remained 
constant between Weeks 5 and 10, and any further changes during this period 
were due to block. All %BF data are given in Appendix C.8-C.9.
4.4. TISSUE WEIGHTS AND PROTEIN ANALYSES
The wet weights (g) of all organs and skeletal muscles are listed by block 
in Table 4.4. The block effect was highly significant for all tissues. In general,
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Figure 4.7. Fat Weight (FAT) at Week 5.
Values are mean + standard deviation.
Significant treatment X block interaction, p = 0.01.
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Figure 4.8. Fat Weight (FAT) at Week 10.
Values are mean + standard deviation.
Significant treatment X block interaction, p = 0.06.
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Figure 4.9. Percent Body Fat (%BF) at Week 5.
Values are mean + standard deviation.
Significant treatment X  block interaction, p = 0.02.
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Figure 4.10. Percent Body Fat (%BF) at Week 10.
Values are mean + standard deviation.
Significant treatment X  block interaction, p = 0.09.
Table 4.4. Organ and Skeletal Muscle Wet Weights by Block at Week 12.
Tissue
Wet Weight (g)
p (for Block)Block 1 Block 2 Block 3
Heart .7689 (.0674) .8786 (.0836) .8938 (.0721) 0.01 (2, 3 > 1)
Liver 8.408 (.895) 10.649 (1.170) 10.113 (1.013) 0.01 (2 > 3 > 1)
Kidneys 2.014 (.191) 2.388 (.206) 2.403 (.182) 0.01 (2, 3 > 1)
Epidiymal Fat 3.936 (1.305) 5.640 (1.266) 4.638 (.720) 0.01 (2 > 3 > 1)
Right Soleus .1487 (.0224) .1712 (.0221) .1543 (.0220) 0.01 (2 > 1, 3)
Right Plantaris1 .4255 (.0552) .4897 (.0536) .4617 (.0533) 0.01 (2 > 3 > 1)
Right EDL .1426 (.0280) .1711 (.0208) .1626 (.0198) 0.01 (2, 3 > 1)
Left Soleus .1487 (.0202) .1650 (.0153) .1547 (.0175) 0.01 (2 > 1, 3)
Left Plantaris .4323 (.0523) .4996 (.0569) .5089 (.0438) 0.01 (2, 3 > 1)
Left EDL .1420 (.0153) .1669 (.0146) .1619 (.0136) 0.01 (2, 3 > 1)
Body Weight2 339.8 (27.1) 418.1 (31.9) 394.6 (34.0)
Values are mean ± standard deviation.
1There was also a significant treatment effect, p = 0.08 (1500. 150. 300. 0, 75, 600). 
Significant treatment X block interaction, p = 0.04.
the highest tissue weights were for Blocks 2 and/or 3, followed by Block 1. The 
only significant treatment effect was for the right plantaris. In this case, 
Treatment 1500 resulted in significantly higher values than Treatments 0, 75, and 
600, and Treatments 150 and 1500 had higher values than Treatments 75 and 
600. As seen with the BW measured by DEXA at Week 10, there was a 
significant treatment X block interaction for BW at Week 12. This interaction can 
be seen in Figure 4.11. The same trend for Block 1 to decrease in BW with 
increasing CrPic dosages was seen, but it also appeared that BW tended to 
increase with CrPic dosage for Block 3. Therefore, the treatment X block 
interaction for BW was slightly more significant at Week 12 than at Week 10. All 
tissue wet weights are given in Appendix D.1-D.11.
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Figure 4.11. Body Weight (BW) at Week 12.
Values are mean + standard deviation.
Significant treatment X  block interaction, p = 0.04.
76
The relative wet weights (g/kg BW) of all tissues are listed by block in 
Table 4.5. There were no significant interactions or treatment effects, but the 
block effect was significant in all cases except for the right EDL. Other than for 
the liver and epididymal fat pads, the block effect for relative weights was 
essentially opposite that of the absolute weights. For relative weights of both the 
heart and skeletal muscles, Block 1 had greater values than Blocks 2 and/or 3. 
All tissue relative wet weights are given in Appendix D.12-D.21.
The values for the dry weights of the left hindlimb muscles are given in 
Table 4.6. There were no significant interactions or treatment effects, but the 
same block effect was evident as with the muscle wet weights. For all three 
hindlimb muscles, block was highly significant, with Blocks 2 and 3 having 
greater dry weights than Block 1. All dry weight means are listed in Appendix
D.22-D.24.
The dry:wet weight ratios for all three hindlimb muscles are also given by 
block in Table 4.6. There were no significant interactions, block or treatment 
effects for the dry:wet weight ratios. All dry:wet weight ratio means are given in 
Appendix D.25-D.27.
Although no changes in LBM or any of the tissue weights were seen due 
to CrPic treatment, preliminary protein analyses were conducted on the left 
plantaris muscle. The myofibrillar and total protein values (mg/g wet weight) of 
the left plantaris are listed by treatment and by block in Table 4.7. There were 
no significant treatment X block interactions. There was a significant treatment
Table 4.5. Organ and Skeletal Muscle Relative Wet Weights by Block at Week 12.
Relative Wet Weight (g /  kg BW)
Tissue Block 1 Block 2 Block 3 p (for Block)
Heart 2.265 (.132) 2.115 (.192) 2.274 (.193) 0.01 (1, 3 > 2)
Liver 24.72 (1.17) 25.42 (1.35) 25.68 (2.04) 0.06 (2, 3 > 1)
Kidneys 5.930 (.326) 5.713 (.305) 6.115 (.506) 0.01 (3 > 1 > 2)
Epidiymal Fat 11.50 (3.39) 13.44 (2.62) 11.80 (1.79) 0.02 (2 > 1, 3)
Right Soleus .4378 (.0593) .4096 (.0443) .3925 (.0570) 0.01 (1 > 2, 3)
Right Plantaris 1.251 (.121) 1.173 (.118) 1.173 (.128) 0.03 (1 > 2, 3)
Right EDL .4196 (.0760) .4102 (.0471) .4130 (.0453) N.S.
Left Soleus .4377 (.0462) .3952 (.0319) .3929 (.0400) 0.01 (1 > 2, 3)
Left Plantaris 1.278 (.121) 1.198 (.135) 1.295 (.118) 0.01 (1,3 > 2 )
Left EDL .4183 (.0327) .3993 (.0222) .4115 (.0315) 0.04 (1 > 2)
Values are mean ±  standard deviation.
Table 4.6. Skeletal Muscle Dry Weights and Dry:Wet Weight Ratios by Block at Week 12.
Tissue
Dry Weight (g)
p (for Block)Block 1 Block 2 Block 3
Left Soleus .0353 (.0049) .0401 (.0041) .0375 (.0041) 0.01 (2 > 3 > 1)
Left Plantaris .1099 (.0117) .1281 (.0132) .1297 (.0119) 0.01 (2, 3 > 1)
Left EDL .0362 (.0036) .0428 (.0037) .0413 (.0035) 0.01 (2, 3 > 1)
Tissue
Dry : Wet Weight Ratios
p (for Block)Block 1 Block 2 Block 3
Left Soleus .2381 (.0171) .2428 (.0085) .2427 (.0099) N.S.
Left Plantaris .2536 (.0107) .2571 (.0171) .2548 (.0066) N.S.
Left EDL .2547 (.0130) .2564 (.0070) .2552 (.0065) N.S.
Values are mean ± standard deviation.
Table 4.7. Left Plantaris Myofibrillar Protein (MP), Total Protein (TP), and MyofibrillanTotal Protein (MP:TP) 
Ratios.
Treatment
0 75 150 300 600 1500
MP (mg/g 57.57 58.79 54.62 54.32 59.16 53.18
wet weight) (8.79) (7.32) (7.80) (8.08) (5.00) (7.40)
TP1 (mg/g 184.02 184.18 171.56 187.37 187.90 173.23
wet weight) (17.15) (19.44) (28.50) (19.81) (7.59) (23.79)
.3139 .3189 .3258 .2911 .3147 .3098
MP:TP (.0450) (.0182) (.0677) (.0400) (.0210) (.0427)
Block
1 2 3
MP2 (mg/g 59.14 53.68 56.00
wet weight) (6.74) (8.49) (6.80)
TP2 (mg/g 188.99 174.43 180.71
wet weight) (18.33) (21.90) (20.33)
.3140 .3089 .3141
MP:TP (.0313) (.0396) (.0548)
Values are mean ±  standard deviation.
’Significant treatment effect, p = 0.09 f600. 300. 75. 0, 1500, 150).
Significant block effect, p = 0.02 for MP (1 > 2) and p = 0.01 for TP (1 > 2). " s ico
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effect for total protein, with Treatments 300 and 600 having higher levels than 
Treatments 150 and 1500. There were significant block effects for both 
myofibrillar and total protein, in which levels for Block 1 were higher than levels 
for Block 2. The myofibrillar:total protein ratios are also given in Table 4.7. 
There were no significant interactions, nor treatment or block effects for these 
values. All protein analyses are given in Appendix D.28-D.30.
4.5. GROWTH RATE. DAILY FEED INTAKE. AND FEED EFFICIENCY 
Values for ADG (g/day) over Weeks 2-11 by treatment and by block are 
given in Table 4.8. There were no interactions or treatment effects, but the block 
effect was highly significant. Average daily gain was greatest for Block 2, 
followed by Block 3, and followed by Block 1. This significant block effect can 
be seen in Figure 4.12. When ADG was broken down into two-week intervals, 
the same trends were seen, although ADG did not differ between blocks by 
Weeks 10-11. Therefore, as seen in Figure 4.13, there was a significant time X 
block interaction. All ADG data are given in Appendix E.1-E.6.
There was a highly significant treatment X block interaction for DFI 
(g/day). The values for DFI by treatment and by block are given in Table 4.8, 
and this significant interaction can be seen in Figure 4.14. As seen in the figure, 
DFI tended to decrease with dosage for Blocks 1 and 2, but it tended to increase 
with dosage for Block 3. Most notably, the highest dosage of CrPic (Treatment 
1500) resulted in the lowest DFI values for Blocks 1 and 2, but it produced the 
highest DFI values for Block 3. Overall, these same trends occurred when DFI
Table 4.8. Average Daily Gain (ADG), Daily feed Intake (DFI), and Feed Efficiency (FE) for Weeks 2-11.
Treatment
0 75 150 300 600 1500
ADG 4.71 4.40 4.68 4.46 4.45 4.68
(g/day) (.45) (.41) (.50) (.44) (.66) (.59)
DFI2 24.58 24.52 24.21 24.02 24.42 22.90
(9/day) (3.60) (2.48) (3.00) (3.40) (1.74) (2.93)
FE2 (g BW/ 14.87 14.00 15.70 15.26 15.53 16.02
kg feed) (2.32) (1.63) (1.95) (1.84) (2.10) (1.99)
Block
1 2 3
ADG1 4.17 4.94 4.58
(g/day) (.37) (.48) (.39)
CMu_o 24.23 25.20 22.89
(g/day) (2.92) (2.75) (2.63)
FE2 (g BW/ 14.44 16.13 15.12
kg feed) (1.41) (2.19) (2.11)
Values are mean ± standard deviation.
’Significant block effect, p = 0.01 (2 > 3 > 1).
Significant treatment X block interaction, p = 0.01 for DFI and p = 0.02 for FE.
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Figure 4.12. Average Daily Gain (ADG) for Weeks 2-11. 
Values are mean + standard deviation. 
Significant block effect, p = 0.01 (2 > 3 > 1).
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Figure 4.13. Average Daily Gain (ADG) in 2-Week Intervals.
Values are mean + standard deviation.
Significant time X "block interaction, p = 0.01.
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Figure 4.14. Daily Feed Intake (DFI) for Weeks 2-11.
Values are mean + standard deviation.
Significant treatment X  block interaction, p = 0.01.
was examined in two-week intervals. Therefore, a significant time X treatment X 
block interaction occurred, as seen in Figure 4.15. As with ADG, DFI did not 
differ between blocks by Weeks 10-11. All DFI data are given in Appendix E.7-
E.12.
Values for FE (g BW/kg feed) over Weeks 2-11 by treatment and by block 
are also listed in Table 4.8. There was a significant treatment X block interaction, 
and this can be seen in Figure 4.16. As seen in the figure, there was a tendency 
for FE to increase with CrPic dosage for Block 2, particularly at the two highest 
levels. Since FE is derived from ADG and DFI, this trend was opposed to what 
occurred for DFI. When FE was broken down into two-week intervals, the 
repeated measures analysis revealed a significant time X block interaction
0& Treatment 0 K H  Treatment 150 □  Treatment 600 
Treatment 75 □  Treatment 300 ^  Treatment 1500
Figure 4.15. Daily Feed Intake (DFI) in 2-Week Intervals.
Values represent the mean.
Significant time X treatment X block interaction, p = 0.02.
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Figure 4.16. Feed Efficiency (FE) for Weeks 2-11.
Values are mean + standard deviation.
Significant treatment X block interaction, p = 0.02.
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Figure 4.17. Feed Efficiency (FE) in 2-Week Intervals.
Values are mean + standard deviation.
Significant time X block interaction, p = 0.01.
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(Figure 4.17). As with ADG and DFI, FE was equivalent between blocks by 
Weeks 10-11. All FE data are in Appendix E.13-E.18.
CHAPTERS. DISCUSSION
Chromium picolinate supplementation did not have any effect on glucose 
tolerance as measured by resting glucose, insulin, or glycated hemoglobin 
levels. However, the block effects for resting glucose and glycated hemoglobin 
values revealed intrinsic differences in glucose tolerance between the blocks of 
animals.
Unexpectedly, neither the DEXA nor the tissue weight analyses indicated 
any changes in lean body mass for any of the CrPic treatments. Therefore, 
CrPic did not appear to act synergistically with insulin in terms of muscle 
anabolism. This is in contrast to several previous human (48, 54, 88) and animal 
(78, 93,102, 137) studies that have examined CrPic supplementation upon body 
composition. However, one other animal study (56) failed to observe any body 
composition changes in swine after 6 weeks of CrPic (300 ppb Cr) 
supplementation. It is possible that Cr stores in the animals in the current study 
as well as that of Evock-Clover et al. (56) were adequate and that further 
potentiation of insulin’s action on lean body mass was not possible. 
Alternatively, it is likely that both humans and animals respond more favorably 
to Cr supplementation under conditions of stress, since stressors such as high 
glucose (14) and high sucrose (94,156) consumption, physical trauma (23), and 
exercise (5, 7, 9, 13, 30) can increase urinary Cr losses. In support of this, in 
several studies of CrPic supplementation in which lean mass increases were 
seen, the subjects or animals were on an exercise program (48, 54, 78). One
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study of CrPic supplementation of sedentary middle-aged and elderly humans 
(88) showed lean body mass increases, but this could have been due to a 
marginal Cr status, since tissue Cr stores decrease with age (158). However, 
some studies of CrPic supplementation in the swine (102,137) and the lamb (93) 
have found increases in lean body mass in the absence of any overt signs of Cr 
deficiency or stress to the animals. Since these three studies (93, 102, 137) 
observed increases in lean mass at dietary levels of 100-250 ppb Cr, as well as 
at the higher level of 1000 ppb Cr in one case (102), differences in CrPic levels 
could not have accounted for the lack of effect on lean body mass seen in the 
current study. However, it is possible that some animals may respond to Cr 
differently, and/or that some species may be more prone to marginal Cr 
deficiencies.
Even though the diet used in this study was high in sucrose (50% by 
weight), this form of dietary stress did not appear sufficient to cause a 
compromised Cr status that could be enhanced by CrPic supplementation, at 
least in terms of lean body mass increases. It seems likely that exercise is an 
important stimuli for the maximum synergistic effects of CrPic supplementation 
upon insulin action in skeletal muscle. Physical training enhances insulin 
sensitivity, which is probably due to enhanced binding of insulin to the receptor 
of the muscle cells (109). Furthermore, subjects with better insulin sensitivity 
may respond more favorably to Cr supplementation (4).
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As seen in several previous human (48, 88) and animal (93, 102, 137) 
studies, CrPic supplementation had a effect on body fat, at least in the Block 1 
animals in this study. The DEXA analyses of FAT and %BF at both Weeks 5 and 
10 demonstrated a decrease in body fat levels for these animals that 
corresponded to increasing CrPic dosage. This decrease in body fat was 
accompanied by a decrease in body weight at Weeks 10 and 12. Therefore, 
these animals experienced a decrease in body fat while maintaining lean body 
mass, resulting in a decreased body weight.
When examining possible causes for this decrease in body fat, there was 
a trend for feed intake to decrease with increasing CrPic dosage, although this 
did not appear to be significant. Therefore, the major cause of this body fat 
decrease appeared to be due to an enhancement of insulin-induced 
thermogenesis rather than an inhibition upon appetite and feed intake. At the 
very highest dosage (1500 ppb Cr), however, there did appear to be a decrease 
in feed consumption for both Blocks 1 and 2. This corresponds with the findings 
of Page et al. (137), who found that feed intake decreased with dosages of 400 
and 800 ppb Cr, but not with dosages of 100 and 200 ppb Cr. Even though 
there were significant treatment X block interactions for body weight at Weeks 
10 and 12 in this study, such was not the case for average daily gain. However, 
there were significant treatment X block interactions for daily feed intake and 
feed efficiency over Weeks 2-11. Daily feed intake appeared to decrease with 
CrPic dosage for Blocks 1 and 2, but it tended to increase with dosage for Block
3. The decrease in daily feed intake corresponded with fat and weight losses 
in Block 1 but not in Block 2, since feed efficiency increased with CrPic dosage 
for the Block 2 animals. In contrast, feed efficiency did not appear to vary with 
dosage for Block 1, and it tended to decrease with dosage for Block 3 at the 
higher CrPic levels. Therefore, changes in feed intake in Block 2 and 3 were 
offset by opposing changes in feed efficiency, so that changes in growth rate 
were not affected by dietary treatment.
The largest differences seen in this study were between blocks, not 
treatments. The Block 2 animals had the greatest average daily gain and lean 
body mass, followed by Block 3, and then by Block 1. The tissue weights, 
including organs, epididymal fat, and skeletal muscles, followed this same trend. 
Additionally, the relative epididymal fat was greater in Block 2 than Blocks 1 and
3. Therefore, the Block 2 animals were heavier and fatter than the Block 3 
animals, followed by the Block 1 animals. This was reflected by the glucose 
tolerance data in which Block 2 had significantly greater resting glucose values 
than Block 1, and Blocks 2 and 3 had higher glycated hemoglobin values than 
Block 1. Therefore, the Block 1 animals may have responded to the CrPic 
treatment because of a greater insulin sensitivity. Anderson (4) has found that 
subjects with increasing degrees of glucose intolerance are less likely to respond 
to supplemental Cr. In other words, subjects with better insulin sensitivity from 
the start may respond more favorably to Cr supplementation than those who are
more insulin resistant, unless, of course, the insulin resistance is a direct result 
of Cr deficiency.
Alternatively, the Block 1 animals may have been more Cr-deficient than 
the Block 2 and 3 animals. Although this would be supported by their lower 
growth rates and body weight values, this was not supported by the blood 
glucose and glycated hemoglobin values. It is also possible that Blocks 2 and 
3 would have responded to the CrPic treatments if they had been placed under 
stress, such as exercise (78) or a low-protein diet (119).
Although Block 1 experienced changes in body composition that 
correlated with CrPic dosage, such was not the case for the Block 2 and Block 
3 animals. Furthermore, other than a depression of feed intake at the very 
highest CrPic dosage, these changes for Block 1 took place without any 
concurrent changes in feed consumption or efficiency.
On the other hand, the Block 2 animals decreased feed consumption with 
increasing CrPic dosage. Since there was no treatment effect for growth rate, 
the feed utilization was inversely related to feed consumption, and it therefore 
increased with CrPic dosage. However, no treatment effects on body 
composition variables (i.e., BW, LBM, FAT, %BF) were observed for this group 
of animals. Page et al. (137) also reported a decrease in feed intake at the 
higher levels of 400 and 800 ppb Cr as CrPic in the swine. It is possible that Cr 
supplementation in these cases potentiated the action of insulin to inhibit 
hypothalamic neuropeptide Y production (91, 164). Since neuropeptide Y
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stimulates feeding (91, 164), its suppression would result in a decrease in feed 
intake. Furthermore, this effect would be greater in a high-carbohydrate versus 
a high-fat diet (15), since neuropeptide Y selectively enhances carbohydrate 
consumption (165). The carbohydrate and fat sources of the diet used in this 
study accounted for approximately 70% and 10% of the total energy content, 
respectively (See Appendix A for diet composition.). Therefore, if Cr facilitated 
a reduction in neuropeptide Y levels, depression of feed intake of this diet would 
be expected to occur. This could also account for the decrease in feed 
consumption by the Block 1 animals at the very highest level of CrPic dosage.
However, for the Block 2 animals, a decreased feed intake did not result 
in decreases in fat or body weight. This was because feed efficiency increased 
as feed consumption decreased with CrPic dosage. In other words, the Block 
2 animals gained more weight, both in terms of total weight and fat weight, per 
amount of diet consumed at the higher CrPic levels.
No previous studies of CrPic supplementation (27, 56, 102, 137) have 
reported significant changes in feed utilization. Although one study (137) 
observed a decrease in daily feed intake, a concurrent decrease in average daily 
gain occurred, so that feed efficiency remained unchanged. However, both feed 
intake and utilization increased in response to supplementation with high-Cr 
yeast in calves (34), and feed utilization was also found to increase in two 
studies of CrCI3 supplementation in swine, although daily feed intake was not 
reported (137, 174). Therefore, in the few Cr supplementation studies in which
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a change in feed efficiency was seen (34, 56, 137), the alteration, like that seen 
for the Block 2 animals of this study, has been an increase.
This increase in feed efficiency could have occurred if Cr potentiated the 
peripheral anabolic actions of insulin in addition to the central effect of 
depressing appetite. An increase in body weight per unit of feed consumption 
could have occurred due to the anabolic actions of insulin, including increased 
cellular uptake of glucose and amino acids (81), increased ribosomal 
translational activity (81), increased glycogen synthase activity (22), and 
suppression of enzymatic catabolism of amino acids and protein (57). 
Furthermore, increased fat stores per unit of feed intake could have occurred if 
Cr potentiated peripheral insulin activity by increasing adipocyte fatty acid 
uptake, increasing hepatic and adipocyte lipogenesis, and/or inhibiting fatty acid 
oxidation in the liver (76, 189).
Therefore, a decrease in daily feed intake with an increase in feed 
efficiency without any concurrent changes in growth rate or body composition 
could have occurred if Cr potentiated the actions of insulin to: 1) suppress 
neuropeptide Y production without stimulating dietary-induced thermogenesis; 
and 2) enhance peripheral anabolic effects in muscle and adipose tissue. 
Furthermore, a decreased feed intake could lead to a reduction in 
thermogenesis, since total carbohydrate intake would be reduced. This would 
promote the retention of body weight in the face of diminished caloric intake.
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Although the Block 2 animals had a depression of feed intake with CrPic 
dosage and the Block 1 animals had a reduced feed consumption at the highest 
CrPic level, such was not the case for the Block 3 animals. For these animals, 
daily feed intake tended to increase with CrPic dosage. Although the results 
were somewhat erratic, the feed intake was greatest for the two highest CrPic 
levels. An enhancement of feed consumption was also reported in one other 
study of CrPic supplementation (137), although it was at the lower levels of 100 
and 200 ppb Cr. Another experiment by the same authors (137) reported that 
higher levels of CrPic (400 and 800 ppb Cr) depressed rather than enhanced 
daily feed intake. As in this block of animals, no changes in feed efficiency 
accompanied the changes seen in daily feed intake (137). Only one other study 
(34) observed an increase in feed consumption, and it was for high-Cr yeast (400 
ppb Cr) supplementation in the calf. In this case, however, growth rate and feed 
efficiency also increased (34). Therefore, although previous studies have found 
somewhat erratic results (34, 137), this is the first study to report an increase in 
daily feed intake at the higher levels of 600 and 1500 ppb Cr.
Since the central effects of insulin tend to decrease rather than increase 
appetite, these effects did not appear to have been potentiated by Cr 
supplementation in this case. However, most of the peripheral effects of insulin 
would lead to an increase in appetite, thereby increasing feed intake (111). 
Insulin lessens the ability of fat stores to spare carbohydrate through the 
reduction of lipolysis (105). The availability of glucose to the insulin-dependent
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hypothalamic glucoreceptors would also be diminished by the enhancement of 
peripheral insulin actions (191), due to preferential oxidation of glucose (189), 
inhibition of gluconeogenesis (136), promotion of glycogen storage (22), and 
stimulation of lipogenesis from carbohydrate (189). Furthermore, peripheral 
insulin acts to reduce the signals from hepatic glucose-sensitive afferent nerve 
fibers upon the vagus nerve to diminish appetite (133). Therefore, if satiety 
centers within the hypothalamus are not intact, the central effects of insulin to 
depress appetite and to increase dietary-induced thermogenesis could not 
occur, resulting in hyperphagia and an accompanying weight gain (24).
Therefore, if Cr supplementation did not potentiate central insulin actions 
upon the hypothalamus to depress feed intake and/or to increase 
thermogenesis, the peripheral effects of insulin to increase appetite and to 
enhance weight gain may have occurred. Although growth rate did not differ 
significantly between treatment groups for Block 3, the average daily gain was 
highest for the animals who received the highest CrPic dosage, and this same 
trend was reflected by the higher body weight of these animals at Week 12. 
Therefore, since feed efficiency did not appear to be affected by CrPic 
supplementation, a trend towards an increase in feed intake correlated with 
increases in growth rate and body weight. If CrPic supplementation had 
enhanced thermogenesis, we would have expected to see a reduction in feed 
efficiency, resulting in no increase or even a decrease in daily gain and body 
weight.
All three blocks of animals appeared to respond to CrPic supplementation 
with changes in feed consumption, although the responses differed between 
groups. In addition, the Block 2 animals appeared to respond to CrPic dosage 
with an increase in feed utilization. However, it was only the Block 1 animals that 
responded to CrPic supplementation with changes in body composition (i.e., 
BW, FAT, %BF). Other than the feed characteristic and body composition data, 
no other treatment effects were observed for any of the blocks of animals. The 
central and peripheral effects of insulin on daily feed intake and on body weight, 
including both lean and fat tissue, have been discussed. Although selective Cr 
potentiation upon the actions of insulin at central and/or peripheral levels could 
account for the different responses between blocks of animals, why different 
animals would respond differently is unclear. Perhaps, due to genetic 
differences, animals have varying sensitivities to insulin at different tissue sites. 
Such sensitivities could depend upon factors such as the number of insulin 
receptors and/or the affinity of the receptors for insulin. For example, if an 
animal possesses a sufficient number of intact hypothalamic insulin receptors 
and insulin-dependent glucoreceptors, Cr potentiation should result in a 
decrease in feed intake. Furthermore, an increase in dietary-induced 
thermogenesis should also occur if sympathetic afferents activate catecholamine 
release by the adrenal gland. On the other hand, if peripheral insulin 
responsiveness to Cr supplementation is enhanced to a greater degree than is 
central activity, an increase in appetite is likely to occur. Additionally, peripheral
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responsiveness of insulin to Cr should enhance the development of both lean 
and fat tissue due to enhanced anabolic and decreased catabolic processes in 
these tissues.
In support of genetic differences between animals possibly accounting for 
the differences in response to CrPic supplementation, there were significant 
differences between blocks for resting blood glucose and glycated hemoglobin 
levels, lean body mass at both Weeks 5 and 10, almost all tissue weights at 
sacrifice, and average daily gain. As mentioned earlier, higher resting glucose 
levels for Block 2 than for Block 1, and higher glycated hemoglobin levels for 
Blocks 2 and 3 versus Block 1, indicated that Block 1 was somewhat more 
insulin sensitive than the other two blocks. Furthermore, for lean body mass, 
most absolute tissue weights, and average daily gain, Block 2 was greater than 
Block 3, which was greater than Block 1. Therefore, factors other than dietary 
treatment were more important in terms of these variables. When tissues were 
expressed in relative terms, however, skeletal muscle weights were generally 
higher for Block 1 than for both Blocks 2 and 3. Furthermore, the relative 
epididymal fat pad weight was greater for Block 2 than for Blocks 1 and 3. 
Therefore, the Block 1 animals appeared to be relatively leaner than the animals 
of Blocks 2 and 3, independent of any treatment effects. Again, this was 
reflected by the resting glucose and glycated hemoglobin data. Since the Block 
1 animals were somewhat more insulin sensitive than the Block 2 and Block 3 
animals, genetic differences could have accounted for differential effects of CrPic
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supplementation upon feed characteristics and body composition. The 
possibility of genetic differences between the blocks of animals was further 
supported by the fact that the Block 1 animals originated from a different 
breeding colony than the Block 2 and Block 3 animals.
As mentioned earlier, exercise may be an important factor in determining 
the effect(s) that Cr supplementation has upon body composition. Since 
endurance exercise training enhances lipolytic activity in adipose tissue and fatty 
acid oxidation in muscle tissue (38), the peripheral effects of insulin to promote 
fat deposition would be counteracted. Furthermore, human studies have shown 
that exercise potentiates the dietary-induced thermogenesis that occurs in 
response to carbohydrate intake (170, 193). Additionally, animal studies have 
shown the effects of insulin and exercise upon thermogenesis to be synergistic 
(20), and that facultative thermogenesis in response to epinephrine in perfused 
skeletal muscle is enhanced by prior endurance training (146). According to 
McCarty (111), "The thermogenic benefit of CrPic may be comparatively small 
in those who are sedentary or who have little muscle mass." This could help 
explain the reduction in body fat seen in football players after CrPic 
supplementation (48), although two other human studies (48, 80) and one animal 
study (78) of CrPic supplementation in which exercise was a factor did not 
observe reductions in body fat.
The preliminary protein analyses for the left plantaris muscle indicated that 
dietary treatment had no effect on myofibrillar protein content, nor did it have an
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effect on protein quality as assessed by the ratio of myofibrillar to total protein 
levels. Although there was a significant treatment effect for total protein, this was 
most likely a chance finding, since there was no pattern for the findings, and 
since no other lean body mass or tissue weight data showed treatment effects. 
Furthermore, these total protein levels appeared to be indirectly related to the 
weights of the muscles rather than due to any direct effect of treatment. 
However, a significant block effect was discovered, due to greater myofibrillar 
and total protein levels in the muscles of Block 1 than Block 2 animals. 
However, as with the treatment effect for total protein, myofibrillar and total 
protein levels in the muscles appeared to be indirectly related to muscle size, 
since the muscle weights were smaller for Block 1 than Block 2. Additionally, the 
dry:wet weight ratios for the left hindlimb muscles did not differ for treatment or 
block, indicating no differences in water content. Therefore, in this study, CrPic 
treatment appeared to have no significant effects on muscle tissue, either in 
terms of mass, protein content, or water content. This lack of treatment effect 
was seen for all skeletal muscles, regardless of fiber type composition.
Growth rate was not affected by CrPic treatment, although treatment did 
have some effects on feed intake and feed utilization. Therefore, predisposing 
genetic factors appeared to be most important in determining growth rate. 
However, it is likely that an enhanced growth rate would have been seen for 
CrPic supplementation if the animals had been raised under stringent Cr-free 
living conditions (119, 153, 154, 161, 162).
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In summary, CrPic supplementation did not appear to influence growth 
rate or acquisition of lean body mass in the rat. It is possible that exercise 
training is an important factor in the synergistic effects of CrPic upon increases 
in lean mass. Furthermore, no changes due to dietary treatment were seen for 
protein or water content of skeletal muscles, regardless of fiber composition.
However, body fat levels for the Block 1 animals were found to decrease 
with increasing CrPic dosage. The largest reduction in fat levels appeared to 
occur between the 0 and 150 ppb Cr levels, although fat decreases still occurred 
in a nearly linear fashion up to the highest level at 1500 ppb Cr. At the very 
highest level, however, feed intake appeared to decrease. Therefore, in terms 
of possible thermogenic effects, the optimal level of CrPic addition to the diet 
appeared to be 600 ppb Cr. At this level, decreases in body fat were seen, with 
no concurrent decreases in feed consumption.
Unlike the Block 1 animals, body fat levels were not affected by CrPic 
supplementation in the Block 2 and Block 3 animals. However, like Block 1, 
Block 2 had a decreased feed intake at the highest CrPic dosage, whereas Block 
3 had an increased feed consumption at this level. It is possible that these 
different blocks of animals responded differently to CrPic supplementation due 
to differential insulin sensitivities at various tissue sites. This can be explained 
by the fact that the central hypothalamic actions of insulin act to depress 
appetite, whereas most of the peripheral affects of insulin would increase hunger. 
Therefore, the effects of CrPic supplementation upon body fat levels and feed
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consumption appear to vary according to predisposing factors, possibly genetic 
in origin, within the animal.
In conclusion, CrPic supplementation appeared to decrease body fat 
levels with a small decrease in body weight for one group of animals in this 
study. Except for the highest CrPic dosage, these body fat reductions occurred 
without a concurrent decrease in feed intake, implicating a possible thermogenic 
effect of CrPic supplementation. Furthermore, these body composition changes 
took place in the absence of any apparent differences in glucose tolerance 
between treatment groups. Unexpectantly, increases in growth rate and in lean 
body mass were not seen for any of the of animals. It was suggested that more 
stringent Cr-free conditions may be needed for changes in growth rate to be 
seen, and that exercise may be a critical factor in potentiating increases in lean 
body mass.
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Table A. Composition of Basal Diet (AIN-76A 120
Semi-Purified Diet without added Cr).
Casein Purified High Nitrogen 20.0%
DL-Methionine 0.3%
Sucrose 50.0%
Corn Starch 15.0%
Alphacel, Non-Nutritive Bulk 5.0%
Corn Oil 5.0%
Choline Bitartrate 0.2%
AIN Mineral Mix (without added Cr) 3.5%
Calcium Phosphate Dibasic 500.00 g/kg mix
Sodium Chloride 74.00
Potassium Citrate Monohydrate 220.00
Potassium Sulfate 52.00
Magnesium Oxide 24.00
Manganous Carbonate (43-48% Mn) 3.50
Ferric Citrate (16-17% Fe) 6.00
Zinc Carbonate (70% ZnO) 1.60
Cupric Carbonate (53-55% Cu) 0.30
Potassium lodate 0.01
Sodium Selenite 0.01
Sucrose, finely powdered 118.55
AIN Vitamin Mix 1.0%
Thiamine Hydrochloride 600.0 mg/kg mix
Riboflavin 600.0
Pyridoxine Hydrochloride 700.0
Nicotinic Acid 3.0
D-Calcium Pantothenate 1.6
Folic Acid 200.0
D-Biotin 20.0
Cyanocobalamin (Vitamin B-12) 1.0
Retinyl Palmitate (Vitamin A) 1.6
Pre-mix (250,000 lU/g)
DL-alpha-Tocopherol Acetate 20.0
(250 lU/g)
Cholecalciferol (Vitamin D3) 250.0
(400,000 lU/g)
Menadione Sodium Bisulfate 50.0
(Vitamin K)
Sucrose, finely powdered 972.9
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Table B.1. Resting Blood Glucose (mg/dl) Means at Week 11.
Block Treatment Mean
0 75 150 300 600 1500
1 101.57
(26.55)
92.03
(15.16)
89.85
(12.02)
100.03
(9.61)
93.60
(17.99)
94.68
(18.91)
95.15
(15.42)
2 107.07
(31.24)
100.23
(12.19)
108.17
(9.33)
105.80
(8.41)
111.07 
(9.43)
102.70
(10.03)
105.84
(13.66)
3 94.50
(6.04)
78.40
(17.60)
112.00
(7.92)
112.77
(3.70)
100.83
(4.06)
97.73
(3.72)
99.37
(13.99)
Mean 101.04
(21.43)
90.22
(16.23)
101.99
(13.90)
105.58
(8.97)
101.01
(13.76)
98.00
(12.53)
99.88
(14.41)
Significant block effect, p = 0.07 (2 > 1).
( ) = Standard deviation.
Table B.2. Resting Blood Insulin OuU/ml) Means at Week 12.
Block Treatment Mean
0 75 150 300 600 1500
1 11.65 10.47 11.82 9.99 14.91 10.84 11.71
(3-19) (2.82) (2.28) (1.81) (12.35) (3.10) (5.57)
2 9.08 9.72 8.94 11.47 8.62 10.36 9.70
(3.67) (2.57) (2.46) (4.80) (2.58) (2.37) (3.08)
3 10.34 8.42 10.83 12.05 13.84 8.82 10.80
(5.85) (3-17) (3.63) (4.78) (3.47) (1.32) (3.75)
Mean 10.24 9.55 10.51 11.20 12.46 10.00 10.70
(3.65) (2.73) (2.85) (3.87) (7.55) (2.38) (3.99)
No significant treatment or block effects.
( ) = Standard deviation.
Table B.3. Glycated Hemoglobin (%) Means at Week 12.
Block Treatment Mean
0 75 150 300 600 1500
1 3.69 3.65 3.14 3.34 3.56 3.79 3.52
(.33) (1.11) (.74) (.88) (1.14) (1.30) (.93)
2 4.08 3.87 3.72 3.80 3.74 4.01 3.87
(.63) (.39) (.27) (.27) (.22) (.47) (.39)
3 3.85 3.89 3.85 3.51 3.85 4.17 3.85
(.31) (.29) (.56) (.14) (.33) (.44) (.39)
Mean 3.89 3.80 3.57 3.55 3.71 3.99 3.75
(.46) (.66) (.61) (.54) (.67) (.79) (.60)
Significant block effect, p = 0.09 (2, 3 > 1).
( ) = Standard deviation.
Table B.4. Glucose Clearance Rate (%/min) Means at Week 11.
Block Treatment Mean
0 75 150 300 600 1500
1 .376 .322 .274 .331 .283 .309 .317
(.282) (.180) (.224) (.185) (.012) (.086) (.170)
2 .195 .263 .323 .310 .265 .318 .279
(.108) (.064) (.050) (.057) (.226) (.103) (.109)
3 .237 .524 .289 .281 .436 .348 .352
(.062) (.081) (.244) (.125) (.034) (.149) (.152)
Mean .280 .370 .293 .310 .328 .323 .317
(.193) (.157) (.176) (.127) (.141) (.101) (.146)
No significant treatment or block effects.
( ) = Standard deviation.
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Table C.1. Initial Body Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 60.2 60.2 60.0 62.2 62.4 61.6 61.1
(6.5) (6.3) (6.3) (6.4) (5.6) (5.9) (5.7)
2 69.2 67.6 66.8 67.4 67.4 67.2 67.6
(3.7) (4.5) (4.1) (4.2) (5.1) (4.1) (4.0)
3 58.4 56.2 59.6 61.6 61.0 56.0 58.8
(9.8) (6.8) (6.3) (5.5) (4.3) (3-7) (6.2)
Mean 62.6 61.3 62.1 63.7 63.6 61.6 62.5
(8.2) (7.3) (6.3) (5.7) (5.5) (6.4) (5.6)
Significant block effect, p = 0.01 (2 > 1, 3).
( ) = Standard deviation.
N>
Table C.2. Body Weight (g) Means at Week 5.
Block Treatment Mean
0 75 150 300 600 1500
1 288.2 275.0 296.3 282.9 256.9 274.9 279.0
(21.0) (18.7) (22.4) (15.9) (23.0) (17.6) (21.7)
2 320.5 313.5 311.0 321.8 340.4 327.3 322.4
(34.9) (20.7) (32.3) (14.4) (18.9) (8.0) (22.1)
3 280.7 280.7 290.5 295.3 298.7 299.6 290.9
(11.2) (10.8) (16.0) (20.9) (17.1) (16.4) (15.5)
Mean 295.6 288.3 299.0 298.3 294.5 298.0 296.5
(27.4) (23.4) (23.1) (22.8) (40.7) (26.5) (18.9)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table C.3. Body Weight (g) Means at Week 10.
Block Treatment Mean
0 75 150 300 600 1500
1 369.9 353.4 376.3 353.0 317.5 346.8 352.8
(22.7) (17.2) (26.9) (22.9) (25.8) (28.5) (28.8)
2 429.5 409.0 410.7 423.8 448.6 424.9 424.4
(37.9) (35.2) (50.1) (21.7) (19.8) (4.8) (29.9)
3 387.5 378.6 390.9 396.3 407.7 399.7 393.4
(14.6) (5.1) (15.1) (16.5) (13.4) (22.1) (16.0)
Mean 393.1 377.6 391.0 387.2 383.9 386.1 386.5
(35.1) (31.1) (32.8) (36.5) (62.4) (40.4) (27.7)
Significant treatment X block interaction, p = 0.07.
( ) = Standard deviation.
Table C.4. Lean Body Mass (g) Means at Week 5.
Block Treatment Mean
0 75 150 300 600 1500
1 232.2 229.1 253.0 240.6 221.8 238.4 235.8
(20.0) (13.7) (22.2) (18.5) (22.1) (9.9) (19.1)
2 270.3 262.9 266.3 268.6 284.3 274.5 271.2
(30.4) (15.7) (32.5) (11.1) (18.3) (11 -8) (19.6)
3 239.2 239.2 246.5 241.9 254.0 255.1 246.0
(8.1) (9.9) (11 -4) (15.2) (11 -7) (7.4) (11 -4)
Mean 245.8 242.3 255.0 249.4 250.2 254.3 249.5
(25.5) (19.0) (22.3) (19.2) (31.9) (18.0) (17.2)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table C.5. Lean Body Mass (g) Means at Week 10.
Block Treatment Mean
0 75 150 300 600 1500
1 296.6 291.3 322.6 298.6 269.8 300.5 296.5
(17.9) (12.1) (26.1) (23.8) (24.3) (26.3) (25.3)
2 357.3 337.4 343.0 340.2 374.9 351.9 350.8
(29.3) (29.8) (51.5) (7.4) (20.9) (14.8) (27.8)
3 333.2 326.4 335.7 329.2 341.9 339.3 334.3
(14.4) (10.7) (11 -8) (19.7) (11 -3) (14.7) (13.1)
Mean 325.8 315.7 332.6 320.3 322.9 327.6 324.1
(32.8) (27.1) (30.5) (25.6) (51.0) (29.9) (18.6)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table C.6. Fat Weight (g) Means at Week 5.
Block Treatment Mean
0 75 150 300 600 1500
1 56.0 46.0 43.4 42.3 35.1 36.5 43.2
(3.1) (12.2) (3.3) (3.9) (2.1) (7.7) (9.0)
2 50.1 50.6 44.7 53.2 56.1 52.8 51.3
(4.6) (8.0) (2.9) (8.9) (10.2) (5.1) (7.0)
3 41.4 41.5 44.0 53.4 44.7 44.4 44.9
(3.6) (2.1) (5.6) (8.5) (5.4) (11 -0) (7.0)
Mean 49.9 46.0 44.0 48.9 44.3 43.8 46.1
(7.2) (8.9) (3.6) (8.4) (10.7) (10.2) (8.2)
Significant treatment X block interaction, p = 0.01.
( ) = Standard deviation.
Table C.7. Fat Weight (g) Means at Week 10.
Block Treatment Mean
0 75 150 300 600 1500
1 73.4 62.1 53.7 54.4 47.7 46.3 56.3
(8.3) (15.4) (4.2) (2.3) (3.4) (4.9) (11.7)
2 72.2 71.6 67.7 83.5 73.7 73.0 73.6
(9.1) (17.4) (1.8) (18.4) (20.1) (16.3) (13.7)
3 54.3 52.2 52.6 67.1 65.8 60.3 58.7
(4.6) (5.7) (9.5) (7.9) (13.1) (9.5) (9.7)
Mean 67.3 62.0 57.6 66.9 60.9 58.5 62.2
(11.3) (14.7) (8.7) (15.9) (16.5) (15.0) (10.3)
Significant treatment X block interaction, p = 0.06.
( ) = Standard deviation.
Table C.8. Percent Body Fat Means at Week 5.
Block Treatment Mean
0 75 150 300 600 1500
1 19.5 16.7 14.7 15.0 13.7 13.2 15.5
(1.5) (3.6) (1.5) (2.0) (1.1) (2.0) (2.8)
2 15.7 16.1 14.5 16.5 16.4 16.1 15.9
(-4) (2.0) (1.7) (2.3) (2.8) (1.8) (1.8)
3 14.7 14.8 15.1 18.0 14.9 14.7 15.4
(■8) (■7) (1.3) (2.1) (■9) (2-9) (1.9)
Mean 16.9 15.9 14.8 16.4 14.9 14.5 15.6
(2.4) (2.4) (1.4) (2.3) (1.9) (2.4) (2.2)
Significant treatment X block interaction, p = 0.02.
( ) = Standard deviation.
Table C.9. Percent Body Fat Means at Week 10.
Block Treatment Mean
0 75 150 300 600 1500
1 19.8 17.5 14.3 15.5 15.1 13.4 15.9
(1.6) (3-7) (1.4) (1.4) (1.2) (1.4) (2.8)
2 16.8 17.5 16.7 19.6 16.4 17.2 17.4
(■8) (3.9) (2.5) (3.3) (4.3) (3.7) (3.0)
3 14.0 13.8 13.4 17.0 16.1 15.1 14.9
(1.2) (1.7) (1.9) (2.3) (2.9) (1.7) (2.2)
Mean 17.2 16.4 14.8 17.2 15.8 15.0 16.0
(2.8) (3.4) (2.2) (2.7) (2.6) (2.7) (2.3)
Significant treatment X block interaction, p = 0.09.
( ) = Standard deviation.
APPENDIX D. TISSUE WEIGHTS AND PROTEIN ANALYSES DATA
136
Table D.1. Left Ventricular Heart Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .8204
(.0928)
.7541
(.0648)
.7847
(.0763)
.7665
(.0473)
.7268
(.0297)
.7612
(.0705)
.7689
(.0674)
2 .8539
(.1239)
.8934
(.0442)
.8532
(.0867)
.8526
(.1124)
.9277
(.0503)
.8907
(.0694)
.8786
(.0836)
3 .9021
(.0376)
.8795
(.0565)
.9231
(.1278)
.8470
(.0530)
.8761
(.0634)
.9349
(.0574)
.8938
(.0721)
Mean .8588
(.0920)
.8423
(.0829)
.8537
(.1091)
.8221
(.0819)
.8435
(.0995)
.8623
(.0978)
.8471
(.0744)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
Table D.2. Liver Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 9.036
(1.186)
8.454
(.548)
8.896
(.936)
8.370
(.683)
7.576
(.641)
8.114
(.760)
8.408
(.895)
2 11.158 
(1.229)
9.916 
(1.369)
10.494 
(1.600)
10.466
(.925)
11.192 
(1.013)
10.670
(.819)
10.649
(1.170)
3 10.226 
(1.038)
9.368
(.236)
9.992
(1.247)
9.802
(.770)
10.222
(.535)
11.066
(1.372)
10.113
(1.013)
Mean 10.140 
(1.396)
9.246 
(1.013)
9.794 
(1.379)
9.546
(1.169)
9.663 
(1.730)
9.950
(1.652)
9.723 
(1.026)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table D.3. Kidney Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 2.140 1.992 2.082 2.102 1.850 1.920 2.014
(.189) (.133) (.233) (.225) (.099) (.122) (.191)
2 2.466 2.358 2.320 2.246 2.422 2.514 2.388
(.203) (.150) (.302) (.188) (.079) (.226) (.206)
3 2.418 2.354 2.412 2.298 2.452 2.486 2.403
(.134) (.187) (.247) (.213) (.154) (.169) (.182)
Mean 2.341 2.235 2.271 2.215 2.241 2.307 2.268
(.222) (.230) (.282) (.212) (.306) (.328) (.193)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
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Table D.4. Epididymal Fat Pad Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 4.822 
(1.487)
4.568
(2.121)
3.954
(1.138)
3.750
(.309)
2.742
(.694)
3.782
(.660)
3.936 
(1.305)
2 5.700
(1.186)
5.420 
(1.726)
5.194
(.894)
5.628 
(1.362)
6.190
(1.630)
5.708
(1.110)
5.640
(1.266)
3 4.692
(.661)
4.050
(.758)
4.816
(.836)
4.396
(.376)
4.898
(.440)
4.976
(.966)
4.638
(.720)
Mean 5.071
(1.172)
4.679
(1.625)
4.655 
(1.042)
4.591
(1.117)
4.610
(1.766)
4.822
(1.191)
4.738
(1.097)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table D.5. Right Soleus Wet Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .1489
(.0158)
.1467
(.0244)
.1575
(.0236)
.1581
(.0229)
.1341
(.0242)
.1470
(.0254)
.1487
(.0224)
2 .1788
(.0166)
.1742
(.0293)
.1604
(.0193)
.1700
(.0143)
.1639
(.0221)
.1800
(.0310)
.1712
(.0221)
3 .1527
(.0230)
.1503
(.0109)
.1571
(.0257)
.1520
(.0136)
.1457
(.0345)
.1681
(.0211)
.1543
(.0220)
Mean .1602
(.0222)
.1570
(.0247)
.1583
(.0214)
.1600
(.0179)
.1479
(.0284)
.1651
(.0280)
.1580
(.0222)
Significant block effect, p = 0.01 (2 > 1, 3).
( ) = Standard deviation.
Table D.6. Right Plantaris Wet Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .4312
(.0850)
.4003
(.0494)
.4637
(.0481)
.4266
(.0485)
.3856
(.0434)
.4455
(.0278)
.4255
(.0552)
2 .4800
(.0436)
.4949
(.0726)
.4845
(.0280)
.4822
(.0517)
.4921
(.0699)
.5043
(.0694)
.4897
(.0536)
3 .4388
(.0251)
.4284
(.0702)
.4913
(.0540)
.4625
(.0258)
.4414
(.0608)
.5081
(.0376)
.4617
(.0533)
Mean .4500
(.0573)
.4412
(.0728)
.4798
(.0432)
.4571
(.0468)
.4397
(.0708)
.4860
(.0537)
.4590
(.0541)
Significant treatment effect, p = 0.08 (1500. 150. 300, 0, 75, 600).
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
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Table D.7. Right Extensor Digitorum Longus Wet Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .1411
(.0400)
.1280
(.0140)
.1558
(.0124)
.1458
(.0290)
.1354
(.0418)
.1465
(.0218)
.1426
(.0280)
2 .1764
(.0104)
.1660
(.0107)
.1719
(.0126)
.1604
(.0128)
.1925
(.0207)
.1596
(.0348)
.1711
(.0208)
3 .1694
(.0121)
.1535
(.0203)
.1708
(.0138)
.1563
(.0089)
.1442
(.0181)
.1817
(.0226)
.1626
(.0198)
Mean .1623
(.0279)
.1507
(.0214)
.1662
(.0142)
.1542
(.0187)
.1573
(.0373)
.1626
(.0292)
.1588
(.0229)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
Table D.8. Left Soleus Wet Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .1441
(.0130)
.1499
(.0256)
.1673
(.0239)
.1492
(.0201)
.1401
(.0150)
.1417
(.0175)
.1487
(.0202)
2 .1647
(.0197)
.1677
(.0198)
.1608
(.0134)
.1639
(.0157)
.1645
(.0131)
.1683
(.0165)
.1650
(.0153)
3 .1519
(.0121)
.1478
(.0082)
.1602
(.0265)
.1436
(.0093)
.1517
(.0100)
.1729
(.0207)
.1547
(.0175)
Mean .1536
(.0167)
.1551
(.0201)
.1628
(.0207)
.1522
(.0170)
.1521
(.0158)
.1610
(.0222)
.1561
(.0177)
Significant block effect, p = 0.01 (2 > 1, 3).
( ) = Standard deviation.
Table D.9. Left Plantaris Wet Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .4190
(.0683)
.4064
(.0515)
.4585
(.0575)
.4543
(.0614)
.4097
(.0366)
.4459
(.0257)
.4323
(.0523)
2 .4711
(.0417)
.5246
(.0754)
.5076
(.0437)
.4699
(.0610)
.5348
(.0628)
.4898
(.0429)
.4996
(.0569)
3 .4930
(.0294)
.4859
(.0319)
.5284
(.0536)
.5025
(.0518)
.5093
(.0307)
.5346
(.0564)
.5089
(.0438)
Mean .4610
(.0558)
.4723
(.0725)
.4982
(.0568)
.4755
(.0578)
.4846
(.0700)
.4901
(.0551)
.4803
(.0510)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
Table D.10. Left Extensor Digitorum Longus Wet Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .1388
(.0133)
.1403
(.0061)
.1535
(.0234)
.1439
(.0162)
.1365
(.0144)
.1391
(.0151)
.1420
(.0153)
2 .1736
(.0173)
.1579
(.0163)
.1700
(.0138)
.1603
(.0093)
.1738
(.0150)
.1657
(.0139)
.1669
(.0146)
3 .1586
(.0079)
.1550
(.0078)
.1691
(.0158)
.1577
(.0147)
.1581
(.0074)
.1727
(.0195)
.1619
(.0136)
Mean .1570
(.0193)
.1511
(.0129)
.1642
(.0185)
.1540
(.0147)
.1561
(.0197)
.1591
(.0213)
.1569
(.0145)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
Table D.11. Body Weight (g) Means at Week 12.
Block Treatment Mean
0 75 150 300 600 1500
1 354.4 342.2 358.8 339.8 307.8 335.8 339.8
(23.3) (12.3) (29.1) (26.1) (18.3) (27.1) (27.1)
2 429.8 403.6 407.6 411.8 427.0 429.0 418.1
(29.3) (36.7) (42.4) (26.4) (35.1) (24.1) (31.9)
3 389.0 363.0 416.2 378.6 391.4 429.6 394.6
(19.3) (13.7) (50.7) (16.3) (16.1) (31.3) (34.0)
Mean 391.1 369.6 394.2 376.7 375.4 398.1 384.2
(39.0) (34.3) (46.6) (37.4) (56.5) (52.3) (31.0)
Significant treatment X block interaction, p = 0.04.
( ) = Standard deviation.
Table D.12. Left Ventricular Heart Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 2.310 2.204 2.187 2.259 2.364 2.268 2.265
(.138) (.172) (.126) (.085) (.083) (.143) (.132)
2 1.987 2.220 2.094 2.136 2.179 2.076 2.115
(.251) (.103) (.024) (.350) (.131) (.107) (.192)
3 2.326 2.425 2.227 2.236 2.240 2.190 2.274
(.189) (.161) (.257) (.071) (.165) (.250) (.193)
Mean 2.208 2.283 2.170 2.210 2.261 2.178 2.218
(.245) (.172) (.164) (.204) (.145) (.183) (.172)
Significant block effect, p = 0.01 (1, 3 > 2).
( ) = Standard deviation.
Table D.13. Liver Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 25.42 24.70 24.77 24.63 24.61 24.17 24.72
(1.84) (1.10) (.92) (.49) (1.36) (1.21) (1.17)
2 25.91 24.53 25.64 25.40 26.20 24.85 25.42
(1.36) (2.14) (1.37) (1.19) (.59) (.79) (1.35)
3 26.25 25.82 24.15 25.88 26.11 25.87 25.68
(1.78) (.78) (2.76) (1.55) (.40) (3.54) (2.04)
Mean 25.86 25.02 24.85 25.30 25.64 24.96 25.27
(1.59) (1.48) (1.83) (1.20) (1.11) (2.17) (1.52)
Significant block effect, p = 0.06 (2, 3 > 1).
( ) = Standard deviation.
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Table D.14. Kidney Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 6.039 5.821 5.793 6.181 6.017 5.730 5.930
(.340) (.306) (.262) (.361) (.278) (.306) (.326)
2 5.736 5.862 5.682 5.452 5.695 5.853 5.713
(.217) (.397) (.242) (.236) (.378) (.273) (.305)
3 6.225 6.493 5.829 6.066 6.264 5.812 6.115
(.396) (.565) (.603) (.420) (.272) (.569) (.506)
Mean 6.000 6.059 5.768 5.900 5.992 5.799 5.919
(.367) (.514) (.380) (.461) (.377) (.379) (.379)
Significant block effect, p = 0.01 (3 > 1 >2) .
( ) = Standard deviation.
Table D.15. Epididymal Fat Pad Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 13.55 13.31 10.88 11.10 8.92 11.26 11.50
(3.80) (5.93) (2.36) (1.31) (2.21) (1.71) (3.39)
2 13.20 13.24 12.75 13.63 14.42 13.40 13.44
(2.27) (3.03) (1.83) (3.06) (3.26) (3.16) (2.62)
3 12.04 11.18 11.70 11.64 12.52 11.69 11.80
(1 -32) (2.30) (2.28) (1 -27) (1.17) (2.61) (1.79)
Mean 12.93 12.58 11.78 12.12 11.96 12.12 12.25
(2.56) (3.90) (2.16) (2.21) (3.23) (2.56) (2.60)
Significant block effect, p = 0.02 (2 > 1, 3).
( ) = Standard deviation.
Table D.16. Right Soleus Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .4205
(.0419)
.4272
(.0585)
.4376
(.0425)
.4654
(.0606)
.4379
(.0921)
.4382
(.0698)
.4378
(.0593)
2 .4165
(.0307)
.4297
(.0393)
.3952
(.0454)
.4129
(.0270)
.3846
(.0532)
.4189
(.0661)
.4096
(.0443)
3 .3931
(.0603)
.4147
(.0374)
.3793
(.0599)
.4020
(.0396)
.3709
(.0831)
.3950
(.0704)
.3925
(.0570)
Mean .4100
(.0443)
.4239
(.0432)
.4040
(.0527)
.4268
(.0502)
.3978
(.0781)
.4174
(.0662)
.4133
(.0535)
Significant block effect, p = 0.01 (1 > 2, 3).
( ) = Standard deviation.
Table D.17. Right Plantaris Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 1.211 1.167 1.292 1.259 1.251 1.329 1.251
(.184) (.108) (.079) (.150) (.096) (.041) (.121)
2 1.122 1.226 1.196 1.173 1.148 1.175 1.173
(.142) (.139) (.108) (.134) (.075) (.136) (.118)
3 1.128 1.180 1.192 1.222 1.126 1.190 1.173
(.037) (.184) (.172) (.068) (.138) (.148) (.128)
Mean 1.154 1.191 1.227 1.218 1.175 1.231 1.199
(.133) (.139) (.126) (.119) (.113) (.131) (.122)
Significant block effect, p = 0.03 (1 > 2, 3).
( ) = Standard deviation.
Table D.18. Right Extensor Digitorum Longus Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .3951
(.0949)
.3756
(.0367)
.4351
(.0284)
.4292
(.0801)
.4382
(.1291)
.4357
(.0518)
.4196
(.0760)
2 .4112
(.0251)
.4123
(.0170)
.4233
(.0244)
.3901
(.0295)
.4525
(.0559)
.3717
(.0758)
.4102
(.0471)
3 .4355
(.0223)
.4217
(.0405)
.4135
(.0397)
.4129
(.0219)
.3676
(.0362)
.4267
(.0763)
.4130
(.0453)
Mean .4139
(.0565)
.4052
(.0360)
.4240
(.0306)
.4107
(.0500)
.4195
(.0866)
.4114
(.0702)
.4143
(.0561)
No significant treatment or block effects.
( ) = Standard deviation.
Table D.19. Left Soleus Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .4067
(.0273)
.4374
(.0669)
.4648
(.0334)
.4390
(.0479)
.4544
(.0263)
.4239
(.0588)
.4377
(.0462)
2 .3836
(.0427)
.4150
(.0188)
.3964
(.0366)
.3984
(.0369)
.3858
(.0235)
.3923
(.0337)
.3952
(.0319)
3 .3906
(.0264)
.4067
(.0322)
.3878
(.0650)
.3793
(.0212)
.3882
(.0302)
.4050
(.0596)
.3929
(.0400)
Mean .3936
(.0321)
.4197
(.0431)
.4163
(.0564)
.4056
(.0429)
.4094
(.0412)
.4071
(.0501)
.4086
(.0394)
Significant block effect, p = 0.01 (1 > 2, 3).
( ) = Standard deviation.
Table D.20. Left Plantaris Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 1.178 1.218 1.275 1.339 1.330 1.332 1.278
(.130) (.111) (.065) (.176) (.064) (.091) (.121)
2 1.103 1.298 1.249 1.143 1.255 1.143 1.198
(.147) (.119) (.077) (.157) (.138) (.093) (.135)
3 1.268 1.339 1.284 1.325 1.302 1.255 1.295
(.056) (.082) (.187) (.083) (.068) (.195) (.118)
Mean 1.183 1.285 1.269 1.269 1.295 1.243 1.257
(.129) (.110) (.114) (.162) (.095) (.149) (.125)
Significant block effect, p = 0.01 (1, 3 > 2).
( ) = Standard deviation.
Table D.21. Left Extensor Digitorum Longus Relative Weight (g/kg Body Weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .3919
(.0315)
.4103
(.0195)
.4269
(.0384)
.4228
(.0219)
.4433
(.0378)
.4143
(.0337)
.4183
(.0327)
2 .4039
(.0311)
.3909
(.0093)
.4180
(.0124)
.3898
(.0200)
.4074
(.0234)
.3860
(.0212)
.3993
(.0222)
3 .4078
(.0022)
.4269
(.0121)
.4095
(.0467)
.4163
(.0269)
.4040
(.0164)
.4044
(.0581)
.4115
(.0315)
Mean .4012
(.0247)
.4094
(.0202)
.4181
(.0338)
.4096
(.0260)
.4182
(.0313)
.4016
(.0395)
.4097
(.0288)
Significant block effect, p = 0.04 (1 > 2).
( ) = Standard deviation.
Table D.22. Left Soleus Dry Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .0339
(.0037)
.0352
(.0066)
.0396
(.0064)
.0349
(.0036)
.0331
(.0036)
.0353
(.0048)
.0353
(.0049)
2 .0400
(.0047)
.0404
(.0056)
.0397
(.0027)
.0393
(.0043)
.0402
(.0045)
.0408
(.0043)
.0401
(.0041)
3 .0359
(.0033)
.0353
(.0023)
.0382
(.0058)
.0365
(.0027)
.0368
(.0020)
.0421
(.0045)
.0375
(.0041)
Mean .0366
(.0045)
.0370
(.0054)
.0392
(.0049)
.0369
(.0038)
.0367
(.0044)
.0394
(.0052)
.0376
(.0042)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table D.23. Left Plantaris Dry Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .1044
(.0173)
.1083
(.0092)
.1165
(.0168)
.1117
(.0106)
.1066
(.0072)
.1115
(.0069)
.1099
(.0117)
2 .1217
(.0121)
.1339
(.0199)
.1317
(.0128)
.1251
(.0081)
.1330
(.0148)
.1232
(.0091)
.1281
(.0132)
3 .1268
(.0092)
.1229
(.0087)
.1349
(.0133)
.1280
(.0155)
.1302
(.0061)
.1354
(.0164)
.1297
(.0119)
Mean .1176
(.0158)
.1217
(.0166)
.1277
(.0157)
.1216
(.0132)
.1233
(.0154)
.1234
(.0147)
.1226
(.0123)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
Table D.24. Left Extensor Digitorum Longus Dry Weight (g) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .0350
(.0040)
.0366
(.0023)
.0385
(.0041)
.0358
(.0041)
.0353
(.0033)
.0357
(.0042)
.0362
(.0036)
2 .0445
(.0033)
.0406
(.0036)
.0443
(.0041)
.0411
(.0032)
.0437
(.0043)
.0425
(.0034)
.0428
(.0037)
3 .0406
(.0033)
.0396
(.0019)
.0429
(.0044)
.0410
(.0044)
.0403
(.0019)
.0434
(.0039)
.0413
(.0035)
Mean .0401
(.0052)
.0389
(.0031)
.0419
(.0047)
.0393
(.0044)
.0397
(.0047)
.0405
(.0051)
.0401
(.0036)
Significant block effect, p = 0.01 (2, 3 > 1).
( ) = Standard deviation.
Table D.25. Left Soleus Dry:Wet Weight Ratio Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .2352
(.0113)
.2346
(.0120)
.2367
(.0195)
.2349
(.0159)
.2368
(.0116)
.2501
(.0293)
.2381
(.0171)
2 .2427
(.0052)
.2406
(.0097)
.2471
(.0071)
.2395
(.0040)
.2445
(.0149)
.2426
(.0083)
.2428
(.0085)
3 .2364
(.0042)
.2397
(.0074)
.2391
(.0078)
.2539
(.0045)
.2431
(.0138)
.2440
(.0116)
.2427
(.0099)
Mean .2381
(.0078)
.2383
(.0096)
.2410
(.0127)
.2427
(.0124)
.2414
(.0130)
.2456
(.0178)
.2412
(.0119)
No significant treatment or block effects.
( ) = Standard deviation.
Table D.26. Left Plantaris Dry:Wet Weight Ratio Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .2492
(.0017)
.2603
(.0104)
.2539
(.0089)
.2472
(.0140)
.2610
(.0134)
.2502
(.0072)
.2536
(.0107)
2 .2581
(.0050)
.2553
(.0061)
.2593
(.0090)
.2691
(.0405)
.2488
(.0025)
.2517
(.0045)
.2571
(.0171)
3 .2571
(.0046)
.2528
(.0037)
.2555
(.0059)
.2545
(.0094)
.2559
(.0064)
.2530
(.0100)
.2548
(.0066)
Mean .2548
(.0056)
.2561
(.0075)
.2562
(.0078)
.2569
(.0253)
.2552
(.0096)
.2516
(.0071)
.2552
(.0115)
No significant treatment or block effects.
( ) = Standard deviation.
Table D.27. Left Extensor Digitorum Longus Dry:Wet Weight Ratio Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .2519
(.0066)
.2591
(.0104)
.2520
(.0120)
.2492
(.0138)
.2589
(.0072)
.2571
(.0238)
.2547
(.0130)
2 .2572
(.0085)
.2576
(.0098)
.2602
(.0087)
.2559
(.0056)
.2513
(.0042)
.2565
(.0022)
.2564
(.0070)
3 .2556
(.0101)
.2557
(.0060)
.2535
(.0040)
.2595
(.0069)
.2547
(.0034)
.2521
(.0076)
.2552
(.0065)
Mean .2549
(.0082)
.2574
(.0084)
.2553
(.0090)
.2549
(.0098)
.2549
(.0058)
.2553
(.0136)
.2554
(.0088)
No significant treatment or block effects.
( ) = Standard deviation.
Table D.28. Left Plantaris Myofibrillar Protein (mg/g wet weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 60.68 63.78 54.02 54.38 63.48 58.50 59.14
(9.84) (3.77) (4.58) (4.91) (6.04) (4.69) (6.74)
2 56.22 52.82 53.70 52.90 55.78 50.66 53.68
(10.71) (8.04) (12.43) (9.13) (2.77) (8.45) (8.49)
3 55.82 59.78 56.14 55.68 58.22 50.38 56.00
(6.40) (5.62) (5.74) (10.78) (2.12) (6.73) (6.80)
Mean 57.57 58.79 54.62 54.32 59.16 53.18 56.27
(8.79) (7.32) (7.80) (8.08) (5.00) (7.40) (7.37)
Significant block effect, p = 0.02 (1 > 2).
( ) = Standard deviation.
Table D.29. Left Plantaris Total Protein (mg/g wet weight) Means.
Block Treatment Mean
0 75 150 300 600 1500
1 190.44
(14.21)
198.36
(16.07)
172.16
(26.09)
190.68
(25.04)
193.04
(8.90)
189.26
(9.92)
188.99
(18.33)
2 175.28
(18.18)
169.92
(21.31)
177.88
(19.75)
188.38
(20.70)
183.96
(5.61)
151.18
(27.74)
174.43
(21.90)
3 186.34
(18.54)
184.26
(10.26)
164.64
(40.77)
183.06
(16.72)
186.70
(6.04)
179.26 
(11.77)
180.71
(20.33)
Mean 184.02
(17.15)
184.18
(19.44)
171.56
(28.50)
187.37
(19.81)
187.90
(7.59)
173.23
(23.79)
181.38
(19.78)
Significant treatment effect, p = 0.09 (600. 300. 75. 0, 1500, 150).
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
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Table D.30. Left Plantaris Myofibrillar:Total Protein Ratio Means.
Block Treatment Mean
0 75 150 300 600 1500
1 .3190
(.0488)
.3226
(.0192)
.3172
(.0322)
.2874
(.0313)
.3286
(.0186)
.3094
(.0257)
.3140
(.0313)
2 .3198
(.0411)
.3104
(.0209)
.2996
(.0463)
.2820
(.0482)
.3036
(.0226)
.3380
(.0449)
.3089
(.0396)
3 .3030
(.0529)
.3236
(.0147)
.3606
(.1018)
.3038
(.0444)
.3118
(.0167)
.2820
(.0419)
.3141
(.0548)
Mean .3139
(.0450)
.3189
(.0182)
.3258
(.0677)
.2911
(.0400)
.3147
(.0210)
.3098
(.0427)
.3124
(.0373)
No significant treatment or block effects.
( ) = Standard deviation.
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Table E.1. Average Daily Gain (g/day) Means for Weeks 2-11.
Block Treatment Mean
0 75 150 300 600 1500
1 4.43 4.20 4.42 4.16 3.74 4.08 4.17
(.24) (.10) (■35) (.41) (.27) (.39) (.37)
2 5.09 4.71 4.80 4.88 5.06 5.06 4.94
(.44) (.57) (.61) (.35) (.55) (.41) (.48)
3 4.59 4.28 4.80 4.34 4.56 4.90 4.58
(.39) (.21) (.49) (.20) (.18) (.47) (.39)
Mean 4.71 4.40 4.68 4.46 4.45 4.68 4.56
(.45) (.41) (.50) (.44) (.66) (.59) (.44)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table E.2. Average Daily Gain (g/day) Means for Weeks 2-3.
Block Treatment Mean
0 75 150 300 600 1500
1 7.64 7.04 7.69 7.27 7.03 7.49 7.36
(.83) (.48) (.82) (.53) (.60) (.37) (.63)
2 8.54 7.83 7.97 7.97 8.54 8.06 8.15
(.66) (.84) (.78) (.45) (.55) (.66) (.68)
3 8.04 7.37 8.47 7.59 7.90 8.01 7.90
(.74) (.43) (.70) (.49) (.81) (.58) (.68)
Mean 8.08 7.41 8.04 7.61 7.82 7.85 7.80
(.79) (.66) (.78) (.54) (.89) (.58) (.67)
Significant treatment effect, p = 0.05 (0. 150. 1500. 600. 300. 75).
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
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Table E.3. Average Daily Gain (g/day) Means for Weeks 4-5.
Block Treatment Mean
0 75 150 300 600 1500
1 6.48 6.51 6.74 6.17 5.41 6.02 6.22
(.24) (•65) (.52) (.90) (.40) (.73) (.71)
2 7.38 7.48 7.26 7.60 8.00 7.66 7.56
(.89) (1.16) (.87) (.77) (.68) (.37) (.79)
3 6.47 6.20 7.05 6.83 6.82 7.46 6.80
(.73) (.36) (.42) (.58) (.58) (.44) (.63)
Mean 6.78 6.73 7.01 6.87 6.74 7.04 6.86
(.77) (.93) (.63) (.93) (1.20) (.91) (.76)
Significant treatment X block interaction, p = 0.02.
( ) = Standard deviation.
Table E.4. Average Daily Gain (g/day) Means for Weeks 6-7.
Block Treatment Mean
0 75 150 300 600 1500
1 3.13 3.31 3.61 3.56 2.41 3.03 3.18
(1.41) (.22) (.76) (.73) (.64) (.75) (.86)
2 4.39 4.07 4.36 4.56 4.71 4.24 4.39
(.35) (.98) (.67) (.31) (.58) (.42) (.58)
3 3.70 3.67 4.04 3.43 3.94 4.21 3.83
(.60) (.23) (.62) (.50) (.56) (.59) (.55)
Mean 3.74 3.69 4.01 3.85 3.69 3.83 3.80
(1.00) (.64) (.71) (.72) (1.13) (.81) (.75)
Significant block effect, p = 0.01 (2 > 3 > 1).
( ) = Standard deviation.
Table E.5. Average Daily Gain (g/day) Means for Weeks 8-9.
Block Treatment Mean
0 75 150 300 600 1500
1 3.36 2.91 3.19 2.73 2.79 2.83 2.97
(1.69) (.29) (.51) (.49) (.40) (.19) (.75)
2 3.53 3.31 3.14 2.97 3.53 3.54 3.34
(.58) (.68) (.53) (.30) (.35) (.51) (.51)
3 2.91 2.54 1.97 2.72 2.94 3.27 2.73
(.59) (.25) (1.83) (.36) (.06) (.88) (.90)
Mean 3.97 2.92 2.77 2.81 3.09 3.21 3.01
(1.04) (.53) (1.02) (.38) (.44) (.63) (.70)
Significant block effect, p = 0.01 (2 > 1, 3).
( ) = Standard deviation.
Table E.6. Average Daily Gain (g/day) Means for Weeks 10-11.
Block Treatment Mean
0 75 150 300 600 1500
1 1.56 1.23 .89 1.10 1.03 1.03 1.14
(.59) (.66) (.33) (.66) (.96) (.83) (.67)
2 1.63 .87 1.29 1.30 .50 1.80 1.23
(.87) (1.16) (.79) (.87) (2.99) (1 -45) (1.48)
3 1.82 1.60 2.47 1.11 1.18 1.54 1.62
(.97) (1.20) (1.90) (.99) (1.00) (1.03) (1.21)
Mean 1.67 1.23 1.55 1.17 .90 1.46 1.33
(.77) (1.01) (1.31) (.79) (1.79) (1.10) (.92)
No significant treatment or block effects.
( ) = Standard deviation.
Table E.7. Daily Feed Intake (g/day) Means for Weeks 2-11.
Block Treatment Mean
0 75 150 300 600 1500
1 25.62 23.74 25.65 23.83 25.03 21.53 24.23
(4.70) (1.13) (3.28) (2.54) (1.64) (1 -76) (2.92)
2 26.60 26.16 25.26 27.02 24.19 21.94 25.20
(1.85) (2.79) (2.52) (3.05) (1.54) (1.78) (2.75)
3 21.52 23.66 21.72 21.21 24.03 25.22 22.89
(1.31) (2.71) (1.60) (1.90) (2.19) (3.67) (2.63)
Mean 24.58 24.52 24.21 24.02 24.42 22.90 24.11
(3.60) (2.48) (3.00) (3.40) (1.74) (2.93) (2.81)
Significant treatment X block interaction, p = 0.01.
( ) = Standard deviation.
Table E.8. Daily Feed Intake (g/day) Means for Weeks 2-3.
Block Treatment Mean
0 75 150 300 600 1500
1 17.21 16.31 18.26 18.11 18.13 17.84 17.64
(1.92) (1.63) (2.18) (1.87) (1.17) (1.78) (1.77)
2 18.87 18.84 18.17 18.11 16.70 17.79 18.08
(1.43) (1.31) (2.13) (2.81) (1.24) (1 -54) (1 -82)
3 17.91 20.20 17.69 17.54 19.14 22.19 19.11
(4.06) (2.00) (.96) (1.91) (2.10) (3.38) (2.91)
Mean 18.00 18.45 18.04 17.92 17.99 19.27 18.28
(2.61) (2.27) (1.73) (2.09) (1.78) (3.06) (2.21)
Significant treatment X block interaction, p = 0.04.
( ) = Standard deviation.
Table E.9. Daily Feed Intake (g/day) Means for Weeks 4-5.
Block Treatment Mean
0 75 150 300 600 1500
1 25.39 24.39 24.27 24.83 24.93 22.86 24.44
(5.40) (.68) (2.34) (2.93) (1.39) (1.51) (2.70)
2 27.11 26.21 24.89 28.54 26.19 21.61 25.76
(2.09) (4.62) (3.80) (4.99) (1.13) (1.52) (3.78)
3 22.80 26.33 23.56 22.86 25.92 28.53 25.00
(3.38) (2.62) (1.98) (1.50) (2.55) (3.85) (3.30)
Mean 25.10 25.64 24.24 25.41 25.68 24.33 25.07
(4.03) (3.01) (2.67) (4.02) (1.76) (3-91) (3.25)
Significant treatment X block interaction, p = 0.01.
( ) = Standard deviation.
Table E.10. Daily Feed Intake (g/day) Means for Weeks 6-7.
Block Treatm ent Mean
0 75 150 300 600 1500
1 29.43 23.00 27.56 24.86 25.46 19.95 25.04
(8.91) (1.95) (4.42) (1.83) (3.39) (1.91) (5.13)
2 31.84 32.37 31.93 35.68 30.28 24.58 31.12
(3.29) (4.78) (3.58) (4.51) (2.01) (3.14) (4.76)
3 22.10 23.97 21.90 20.93 25.83 25.23 23.33
(3-21) (3.59) (1.65) (2.29) (3.40) (4.13) (3.41)
Mean 27.79 26.45 27.13 27.16 27.19 23.25 26.50
(6.86) (5.50) (5.30) (7.07) (3.59) (3.83) (4.70)
Significant treatment X block interaction, p = 0.01.
( ) = Standard deviation.
Table E.11. Daily Feed Intake (g/day) Means for Weeks 8-9.
Block Treatment Mean
0 75 150 300 600 1500
1 30.69 29.47 33.14 27.64 32.24 25.45 29.77
(6.72) (3.07) (6.85) (4.92) (3.21) (4.23) (5.33)
2 29.64 29.33 27.83 28.30 25.46 23.39 27.32
(4.69) (1 -67) (2.08) (2.03) (4.48) (2.50) (3.65)
3 21.57 24.40 21.77 22.03 24.76 25.33 23.31
(.36) (4.00) (2.46) (2.88) (2.38) (3.95) (3.10)
Mean 27.30 27.73 27.58 26.00 27.49 24.72 26.80
(6.08) (3.74) (6.28) (4.35) (4.74) (3.51) (4.01)
Significant block effect, p = 0.03 (1 > 2 > 3).
( ) = Standard deviation.
Table E.12. Daily Feed Intake (g/day) Means for Weeks 10-11.
Block Treatment Mean
0 75 150 300 600 1500
1 25.37 25.53 25.04 23.71 24.37 21.57 24.26
(5.02) (2.36) (4.17) (3.45) (1 -79) (2.56) (3.39)
2 25.53 24.06 23.47 24.44 22.32 22.34 23.69
(2.58) (2.77) (2.19) (4.90) (2.08) (2.67) (2.98)
3 23.20 23.41 23.67 22.68 24.51 24.86 23.72
(1.51) (3.08) (2.30) (3.13) (1.66) (3.73) (2.57)
Mean 24.70 24.33 24.06 23.61 23.73 22.92 23.89
(3.31) (2.71) (2.89) (3.69) (2.00) (3.16) (2.87)
No significant treatment or block effects.
( ) = Standard deviation.
Table E.13. Feed Efficiency (g Body Weight/kg Feed) Means for Weeks 2-11.
Block Treatment Mean
0 75 150 300 600 1500
1 14.31 14.44 14.82 14.19 13.47 15.43 14.44
(1.88) (.77) (1.62) (1 -62) (.52) (1.48) (1.41)
2 14.83 14.78 15.71 15.58 17.86 18.02 16.13
(2.17) (1.75) (2.72) (2.26) (.48) (1.01) (2.19)
3 15.47 12.79 16.57 16.01 15.24 14.60 15.12
(3.12) (1.67) (1.19) (1.37) (1.65) (1.65) (2.11)
Mean 14.87 14.00 15.70 15.26 15.53 16.02 15.23
(2.32) (1.63) (1.95) (1.84) (2.10) (1.99) (1.94)
Significant treatment X block interaction, p = 0.02.
( ) = Standard deviation.
Table E.14. Feed Efficiency (g Body Weight/kg Feed) Means for Weeks 2-3.
Block Treatment Mean
0 75 150 300 600 1500
1 44.56 43.40 42.34 40.41 38.76 42.29 41.96
(3.96) (3.82) (4.21) (4.04) (1.83) (4.74) (4.02)
2 45.67 41.66 44.43 44.86 51.28 45.51 45.57
(7.00) (4.92) (7.34) (7.14) (3.40) (4.72) (6.15)
3 46.67 36.89 47.94 43.58 41.55 36.95 42.26
(10.55) (5.32) (3.74) (4.59) (5.28) (7.24) (7.37)
Mean 45.64 40.65 44.90 42.95 43.86 41.58 43.26
(7.15) (5.22) (5.49) (5.38) (6.56) (6.41) (5.94)
Significant treatment X block interaction, p = 0.04.
( ) = Standard deviation.
Table E.15. Feed Efficiency (g Body Weight/kg Feed) Means for Weeks 4-5.
Block Treatment Mean
0 75 150 300 600 1500
1 26.48 26.70 28.06 25.26 21.71 26.37 25.76
(5.48) (2.46) (3.96) (5.45) (.89) (3.21) (4.11)
2 27.35 29.54 29.80 27.16 30.54 35.49 29.98
(3.90) (8.27) (6.25) (4.49) (2.19) (1.61) (5.35)
3 29.00 23.77 30.02 29.95 26.56 26.37 27.61
(6.56) (3.10) (2.39) (2.81) (4.15) (2.39) (4.19)
Mean 27.61 26.67 29.29 27.46 26.27 29.41 27.79
(5.14) (5.47) (4.25) (4.53) (4.53) (5.02) (4.69)
Significant treatment X block interaction, p = 0.04.
( ) = Standard deviation.
Table E.16. Feed Efficiency (g Body Weight/kg Feed) Means for Weeks 6-7.
Block Treatment Mean
0 75 150 300 600 1500
1 11.08 14.44 13.67 14.47 9.61 15.13 13.07
(6.07) (.81) (4.87) (3.72) (2.77) (2.92) (4.10)
2 13.85 13.02 13.85 12.94 15.68 17.36 14.45
(1.38) (4.59) (3.08) (1.86) (2.70) (1.68) (2.99)
3 17.22 15.57 18.41 16.38 15.57 17.00 16.69
(4.28) (2.28) (1.91) (1.32) (3.38) (3.21) (2.83)
Mean 14.05 14.34 15.31 14.60 13.62 16.50 14.74
(4.80) (2.98) (3.96) (2.75) (4.02) (2.68) (3.42)
Significant block effect, p = 0.01 (3 > 1, 2).
( ) = Standard deviation.
Table E.17. Feed Efficiency (g Body Weight/kg Feed) Means for Weeks 8-9.
Block Treatment Mean
0 75 150 300 600 1500
1 11.32 9.94 9.96 10.01 8.75 11.26 10.21
(5.79) (1.10) (2.52) (2.14) (1.82) (1.23) (2.79)
2 12.17 11.32 11.35 10.57 14.13 15.22 12.46
(3-15) (2.37) (2.07) (1 -47) (2.42) (2.33) (2.73)
3 13.52 10.52 8.57 12.46 11.99 12.77 11.64
(2.78) (.76) (8.47) (1 -94) (1.38) (1 -77) (3.88)
Mean 12.34 10.59 9.96 11.01 11.62 13.09 11.44
(3.93) (1 -57) (4.99) (2.04) (2.90) (2.40) (3.05)
Significant treatment effect, p = 0.08 (1500. 0. 600. 300, 75, 150).
Significant block effect, p = 0.02 (2, 3 > 1).
( ) = Standard deviation.
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Table E.18. Feed Efficiency (g Body Weight/kg Feed) Means for Weeks 10-11.
Block Treatment Mean
0 75 150 300 600 1500
1 6.03 4.74 3.66 4.46 4.06 4.94 4.65
(2.02) (2.47) (1.49) (2.60) (3.66) (4.24) (2.75)
2 6.27 3.50 5.48 5.15 1.61 7.65 4.94
(2.97) (4.78) (3.27) (3.12) (14.36) (6.47) (6.73)
3 7.70 6.56 10.32 4.79 4.84 6.01 6.70
(3.91) (4.49) (7.68) (4.54) (4.12) (3.67) (4.88)
Mean 6.67 4.94 6.48 4.80 3.50 6.20 5.43
(2.94) (3.97) (5.38) (3.27) (8.34) (4.73) (4.78)
No significant treatment or block effects.
( ) = Standard deviation.
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